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Melissa Lo Monaco, Greet Merckx, Jessica Ratajczak, Pascal Gervois, Petra 
Hilkens, Peter Clegg, Annelies Bronckaers, Jean-Michel Vandeweerd* and Ivo 
Lambrichts* 
Stem Cells Int. 2018; 2018: 9079538. 




1.1. Musculoskeletal Disorders and the Synovial Joint 
Musculoskeletal disorders (MSDs) include more than 150 different pathologies. 
They can vary from short-term injuries to chronic disorders associated with long-
term discomfort and disability. According to the World Health Organization (WHO), 
musculoskeletal injuries are the most common cause of severe long-term pain 
and physical disability, and affect hundreds of millions of people around the world. 
In addition, they are often leading to significant mental health weakening and 
increased risk of other chronic conditions. Although the prevalence of major 
musculoskeletal conditions increases with age, they are not only affecting older 
people (1). Moreover, the increasing popularity of sports caused a widespread of 
MSDs. They occur to joints, but also to the surrounding soft tissues that contribute 
to their movement; they can affect but are not limited to muscles, bones, joints, 
cartilage, ligaments, and tendons (1). 
 
Figure 1.1. Structure of the human synovial joint. The synovial fluid, produced by the 
synovium or synovial membrane, together with the articular cartilage, which covers the ends 
of bone, allow the frictionless movement of the bones over one another. The joint capsule 
is a fibrous tissue surrounding the joint. The ligaments surrounding the joint prevent over-
flexion or -extension. Tendons stabilize joints, attach skeletal muscles to bones and 
transform the contraction of the muscle into movement of the joint. This image was created 
using Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic 
License, available online at https://smart.servier.com/. 
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Joints or articulations are the connections between bones and can be divided in 
three groups based upon the degree of movement they allow: synarthrosis joints 
allow little or almost no movement, amphiarthrosis joints, such as intervertebral 
discs, permit partial movement and the third group consists of synovial joints or 
diarthrosis (2). The synovial joint (Figure 1.1) is the most common joint in the 
human body and allows free but restricted angular movement of articulating 
bones. It consists of articular cartilage, synovium, synovial fluid, perichondrium, 
and subchondral bone (Figure 1.1) (3). The lubricated surface of the articular 
cartilage covers the ends of bones, allowing the smooth movement of bones at 
the joint site (2, 4). Stability of joints is ensured by soft tissue structures, such as 
tendons or articular ligaments (5). 
Degenerative diseases and overloading of the joint may eventually result in 
irreversible damage to tissues from the joint, comprising articular cartilage and 
tendons. Cartilage injuries are very common, and are especially highly prevalent 
in subjects with knee osteoarthritis (OA) (6), one of the most common and 
debilitating MSDs (1). In addition, 30% of all consultations related to MSDs are 
reported to be tendon-related (7). There is a growth in the prevalence of OA and 
tendinopathies and an increase in costs, leading to a substantial economic impact 
of both conditions. Both pathologies involve tissues that are characterized by a 
low intrinsic regenerative capacity due to the low vascularity and cell content. 
Furthermore, current treatment options are not able to provide full and stable 
recovery of the damaged tissue (8-10). Moreover, despite significantly improved 
knowledge and understanding of the pathophysiology of both diseases, there is 
still an increasing need for the development of new treatment strategies for OA, 
cartilage defects and tendon injuries (11).  
1.2. Cartilage Defects and Osteoarthritis  
1.2.1. Pathophysiology and Current Treatments  
Articular cartilage covers the ends of bone, due to its slightly compressible nature 
and lubricated surface, it provides the joint with shock absorption and lubrication 
(4, 8). Hyaline cartilage is comprised of 95% extracellular matrix (ECM) (dry 
weight) and only 5% of sparsely distributed chondrocytes (12). This matrix 
primarily consists of type II collagen and proteoglycans (PGs). Negatively charged 
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glycoproteins are able to attract water, allowing cartilage to resist compressive 
forces (13). Despite the fact that chondrocytes only make up about 5% of hyaline 
cartilage tissue, they are integral for cartilage function and homeostasis (13). 
These cells are of mesenchymal origin and are responsible for synthesizing 
cartilage ECM (12). Hyaline cartilage is an avascular tissue which, in part, explains 
the limited regeneration following injury. The lack of vasculature makes it difficult 
for progenitor cells to be recruited to the site of injury and hinders the supply of 
nutrients necessary for tissue repair (8, 9).  
Cartilage loss can occur as a consequence of traumatic injury, leading to focal 
defects, or through chronic degeneration. Both partial thickness or full thickness 
cartilage defects occur (14). Since full thickness lesions extend into the 
subchondral bone, they have access to bone marrow cells and therefore have a 
higher probability of spontaneous regeneration than partial thickness lesions, 
which only involve the avascular cartilage tissue (14). Eventually cartilage defects 
will lead to activity-related pain, swelling and decreased mobility and will 
frequently progress to OA (8, 15). In the United States alone, over 27 million 
adults suffer from OA, while in Europe it is estimated to affect more than 40 million 
people, leading to a substantive clinical and financial burden (16-18). 
OA is the most common form of arthritis and affects the large weight bearing 
joints such as hip and knee, but also smaller joints such as digits. Pathological 
changes seen in OA joints include progressive destruction of articular cartilage, 
thickening of the subchondral bone, formation of osteophytes, variable degrees of 
inflammation of the synovium and degeneration of ligaments or tendons and 
menisci of the knee (19).  
For long times, OA has been considered as a disease of cartilage degradation. 
However, improved understanding of the pathophysiology unravelled that the 
disease affects the entire joint, in which matrix proteases play a crucial role. Under 
normal conditions, cartilage matrix is exposed to continuous ongoing remodelling 
in which degenerative and synthetic enzymatic activities are balanced. However, 
in OA cartilage, matrix degrading enzymes are upregulated, which results in 
shifting the balance towards degeneration, release of pro-inflammatory cytokines, 
and eventually evolves in loss of collagen and PGs. In addition, the subchondral 
bone, menisci and ligaments and the synovium have been described to play key 
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roles in OA pathogenesis, and are associated to the pro-inflammatory status of 
the entire joint as well as the systemic inflammation (20-22). Different cellular 
changes and biomechanical stress lead to secondary OA features, including 
subchondral bone remodelling, the development of osteophytes, the formation of 
bone marrow injuries and synovial changes (20).  
There are currently no treatments available to effectively heal cartilage defects. 
When cartilage defects develop into OA, the condition can only be managed by a 
multidisciplinary approach including pharmacotherapy, physiotherapy or joint 
replacement surgery (23). However, several surgical interventions can be 
performed in order to prevent progression towards OA (8). Current techniques 
include: arthroscopic lavage and debridement, microfracture induction and 
autologous chondrocyte implantation (ACI) (11). Although these techniques have 
been proposed to restore normal joint function and minimize further degeneration, 
they often do not offer a long-term clinical solution. There is a clinical need to 
develop regenerative medicine approaches to permanently restore articular 
cartilage (11).  
Within cellular regenerative therapeutic applications, ACI, the use of mesenchymal 
stem cells (MSCs) and platelet concentrates are of particular interest. ACI consists 
of a three-step procedure involving harvesting, culturing and re-implantation of 
autologous chondrocytes into the defect. Nevertheless, the technique can be 
associated with several drawbacks, such as an increased risk for complications, 
iatrogenic damage, the need of two surgeries, and low integration of the 
chondrocyte implantation (24, 25). For these reasons, other regenerative 
approaches, including platelet derivatives and stem cell-based therapies, have 
experienced substantial research attention.  
1.3. Stem-Cell Based Approaches for Cartilage Regeneration 
and Osteoarthritis  
1.3.1. Current In Vitro Evidence of Chondrogenic Differentiation 
of Stem Cells  
For stem cell-based cartilage regeneration, MSCs are of particular interest 
because, in comparison to chondrocytes, they have high availability, and are both 
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easy isolated and expanded (26). In addition, their in vitro chondrogenic 
differentiation potential has been demonstrated (27). More recently, in vitro 
studies on induced pluripotent stem cells (iPSCs) indicated promising results for 
their use in cartilage repair (28, 29). However, a number of challenges need to be 
overcome and further optimization is still needed before both stem cell types can 
be used as a safe and effective therapeutic option for promoting cartilage repair 
(8, 30-33). 
Mesenchymal stem cells 
Adult MSCs were first identified in bone marrow (34, 35), but afterwards, other 
MSC niches have been discovered in both adult and foetal tissues, including 
adipose tissue (36), placenta (37), umbilical cord (38), dental pulp (39), 
peripheral blood (40) and in the synovial membrane (41). As defined by the 
International Society for Cellular Therapy (ISCT), MSCs must be able to 
differentiate into chondrocytes under specific in vitro conditions (42). In addition, 
MSCs possess additional properties making them a suitable cell source for 
cartilage regeneration. High cell numbers can be produced and the 
immunomodulatory characteristics of MSCs allow for their allogeneic use (43). 
Pellet and monolayer cultures are the two main culture systems that have been 
developed to study in vitro chondrogenic differentiation. The three-dimensional 
(3D) pellet system is the most representative in vitro model for the condensation 
of mesenchymal cells that is observed during the initiation phase of 
chondrogenesis in the process of endochondral ossification (44, 45). Moreover, 
co-cultures with chondrocytes in both 2D and 3D culture systems could push MSCs 
towards the chondrogenic lineage (46-48) and growth factors such as insulin-like 
growth factor (IGF) (49), and members of the fibroblast growth factor (FGF) (50) 
and transforming growth factor-beta (TGF-β) (51-53) families, can be added to 
the differentiation medium to enhance chondrogenic differentiation. Additionally, 
the chondrogenic differentiation potential of MSCs and the production of ECM 
proteins can also be stimulated by combining MSCs and biomaterials in 3D 
scaffolds (54-61) or by manipulating the oxygen tension (62).  
In vitro studies mainly focus on bone marrow-derived mesenchymal stem cells 
(BM-MSCs), followed by MSCs derived from adipose tissue and synovial 
membrane because of their easy isolation and close proximity to cartilage and 
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joints, respectively (63). A correlation between the chondrogenic potential of 
MSCs and their tissue source has been suggested. BM-MSCs showed a superior 
chondrogenic differentiation capacity compared to MSCs from other origins (64-
66). These differences might be explained by variations in gene expression and 
pathway activation (67). Therefore, an adapted differentiation protocol for other 
MSC sources could compensate for lower chondrogenic differentiation capacities 
(67, 68).  
Despite their promising chondrogenic potential in vitro, several challenges are 
linked to the use of MSCs in cartilage regeneration. The most common issue is 
terminal differentiation towards hypertrophic cells (45). Moreover, mineralization 
and vascularization have also been reported after transplantation (44, 69). In 
addition, cartilage tissue derived from in vitro differentiated MSCs resembles 
fibrocartilage with inferior mechanical properties and healing capacity (30). 
Another limitation is the inter- and intra-donor heterogeneity of MSCs which could 
influence chondrogenic differentiation potential of cells (70), depending on 
comorbidities, tissue source and culture methods (33).  
Induced pluripotent stem cells 
Part of the issues associated with MSCs can be circumvented by using iPSCs. 
These cells are transformed from fibroblasts to pluripotent stem cells by retroviral 
transduction with the transcription factors Oct3/4, Sox2, Klf4, and c‐Myc, the so‐
called Yamanaka factors, which makes them an ideal patient-specific unlimited 
cell source for autologous tissue regeneration (71). Promising in vitro results have 
already been demonstrated in the cartilage engineering field for iPSCs generated 
from various cell types (28, 29, 31, 72, 73). Nevertheless, Guzzo et al. stressed 
the influence of cell type origin on their chondrogenic capacity, where superior 
properties could be assigned to iPSCs from chondrogenic origin (74), which may 
be due to the preservation of the epigenetic memory (75).  
Analogous to MSCs, indirect co-cultures of iPSCs with primary chondrocytes could 
directly induce the formation of chondrocytes (28). Furthermore, iPSCs could be 
committed to the chondrogenic lineage in high-density pellet culture systems, 
enhanced by the addition of growth factors from the TGF-β superfamily. 
Nevertheless, the resulting cartilage is a heterogeneous combination of 
hypertrophic-, articular- and fibrocartilage (76). This heterogeneity could be 
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reduced by first differentiating iPSCs towards an intermediate cell population, such 
as MSCs (76, 77) or embryonic cell types (31, 73, 78). An alternative approach to 
further enhance the chondrogenic potential is seeding iPSCs into scaffolds, such 
as nanofibrous scaffolds (79).  
Although iPSCs express higher proliferation rates (80) and similar or superior 
chondrogenic differentiation potential (32, 72) compared to MSCs, other 
limitations remain associated with these stem cells. Patient-specific autologous 
iPSC generation and transplantation is very expensive and would therefore not be 
a therapeutic option for all patients. Allogeneic therapy would be more attractive, 
but immune rejection cannot be excluded (81). Analogous to MSCs, it remains 
uncertain whether the regenerated cartilage induced by iPSCs preserves the 
mechanical and functional properties of native articular cartilage. Furthermore, 
also for iPSCs, the presence of hypertrophic signals under in vitro conditions, even 
though to a lesser extent than for MSCs, might indicate the formation of low-
quality cartilage tissue by iPSCs (31, 32). Safety issue is the most important 
concern that hampers their general use (82). The potential reactivation of 
pluripotency in iPSCs or iPSC-derived chondrocytes should be addressed (83). 
Moreover, when using retrovirally transduced iPSCs, where the retroviral gene is 
integrated in the host, a higher risk for teratoma formation in cell transplants is 
reported (84). Therefore, adequate phenotyping of (fully) chondrogenic 
committed iPSCs is needed before transplantation of cells in (pre)clinical use.  
Other Sources 
In addition to the above mentioned stem cell sources, also articular cartilage 
progenitor cells (ACPCs) might present a potential favourable stem cell source 
(85). Though articular cartilage is unable to heal spontaneously, a population of 
stem or progenitor cells from articular cartilage was identified. ACPCs can be found 
in the surface zone of articular cartilage and are responsible for cartilage 
homeostasis (85, 86). They can offer multiple advantages over BM-MSCs, since 
they undergo a more stable chondrogenesis and have been shown to be resistant 
to hypertrophic chondrogenic differentiation (87). Nevertheless, their use is 
hampered by drawbacks such as donor site morbidity or limited availability. 
General Introduction and Aims 
9 
Also skeletal stem cells (SSCs) may have potential and therapeutic function. They 
reside at the growth plate and the periosteum and can differentiate towards bone, 
cartilage, and bone marrow (88, 89). While their function in bone growth and 
homeostasis of the skeleton is recognised, the precise definition of SCCs requires 
a common consensus, mainly because of the distorted similar use of terms of 
SCCs and MSCs (89). This is mainly due to the fact that MSCs have been used to 
describe any cell type with stem cell properties. Bona fide SSCs are bone-resident 
stromal stem cells. Similarly, any other connective tissue contains a comparable, 
but specific stem cell type (89). 
1.3.2. Mechanisms of Action of Stem Cell-based Therapies for 
Cartilage Regeneration and Osteoarthritis  
Stem cell-based therapies were initially developed as a cell replacement therapy 
due to the chondrogenic differentiation potential of stem cells (31, 32, 61, 90, 
91). Moreover, differentiated MSCs, embryonic stem cells (ESCs) and iPSCs 
secrete PGs and collagen type II (31, 92-95) which are essential components of 
cartilage tissue. However, it has been shown that upon intra-articular (IA) 
transplantation, MSCs induce cartilage replacement, but the principle source of 
repair tissue is derived from endogenous cells (96). Therefore, it is postulated that 
the paracrine effect of the transplanted cells on the damaged host environment is 
mainly responsible for stimulating cartilage regeneration (Figure 1.2). MSCs that 
were exposed to tumour necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-
1β), were shown to upregulate the expression of several growth factors, anti-
inflammatory mediators (vide infra) and anti-catabolic factors ultimately leading 
to (stem) cell-mediated cartilage regeneration (Reviewed in (97, 98)). The main 
growth factors associated with cartilage regeneration that are secreted by MSCs 
belong to the TGF-β superfamily (99). Moreover, adipose tissue-derived 
mesenchymal stem cells (AT-MSCs) were demonstrated to diminish matrix 
metalloproteinase (MMP)-13 expression upon transplantation, potentially 
counteracting collagen degeneration in pathological cartilage (100). In addition to 
the paracrine effect of soluble factors, extracellular vesicles (EVs), released by 
MSCs, have been shown to influence cartilage regeneration (Figure 1.2). Reports 
on stem cell EV-mediated cartilage repair are scarce. However, studies showed 
that MSC-EVs promoted the formation of new cartilage and the deposition of 
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collagen type II and glycosaminoglycans (GAGs) (101). Additionally, EVs from 
MSCs that overexpressed miR-140-5p stimulated chondrocyte migration and 
proliferation (102). Moreover, it was recently reported that BM-MSCs secrete 
hyaluronic acid (HA)-coated EVs (103), which may allow MSC homing to cartilage 
defects in receptor-mediated way via CD44. Although stem cell-EVs have shown 
beneficial effects in cartilage repair, it should be noted that EVs may also have 
damaging effects in arthritis (104). 
 
Furthermore, it has been demonstrated that MSCs possess several 
immunomodulatory properties (Figure 1.2) (105). Given the immune component 
underlying cartilage degeneration, modulating the immune response might 
contribute to reducing cartilage loss in diseases where an uncontrolled immune 
response is detrimental (106, 107). In OA, in addition to cartilage destruction, 
substantial synovial inflammation is reported. The secretome of MSCs, rich in anti-
inflammatory cytokines, was demonstrated to balance the immune response in 
the synovium through decreasing the production of inflammatory mediators in OA 
explants (108). 
First, MSCs are reported to inhibit proliferation of both CD4+ and CD8+ T cells in 
a dose-dependent way. Moreover, a shift from Th1 to Th2 inflammatory cells 
combined with a change in inflammatory cytokine profile was induced by MSCs. 
Also the formation of regulatory T cells in vitro and in vivo is assisted via MSCs 
(109). BM-MSCs, for example, have been shown to suppress T-cell proliferation 
(110, 111) and to induce T-cell apoptosis (112). The resulting debris stimulated 
phagocytes to produce TGF-β which increased the number of regulatory T cells 
(112). Moreover, T-cell proliferation was inhibited by BM-MSCs via production of 
prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO), which are two 
main effectors of MSC-mediated immune-suppression (108, 113, 114). PGE2 and 
IDO are also crucial in MSC-mediated inhibition of NK cell activation (115). MSCs 
are reported to inhibit NK cell proliferation and impair cytotoxic activity and NK 
cell cytokine production (109). 
The proliferation, activation, maturation and antigen presentation of dendritic cells 
was also inhibited by MSC subtypes (116-120) and macrophage/microglia 
polarization was shifted towards an anti-inflammatory phenotype after exposure 
to MSCs, their secretome, or EVs (118-123) (reviewed by Weiss et al. (109)). IL-
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1 Receptor Antagonist, secreted by MSCs, is described to promote the polarization 
of macrophages towards a more anti-inflammatory phenotype, which in turn 
secrete high levels of IL-10 and show decreased expression of TNF-a and IL-17. 
Moreover, IL-10 prevents monocyte differentiation into dendritic cells and shifts 
monocytes towards an anti-inflammatory, IL-10-secreting subtype contributing to 
a positive-feedback loop (109). Apart from IL-10, MCS-stimulated monocytes 
express high levels of MHC class II, CD45R, and CD11b and seem to be able to 
suppress T-cell activity. Regardless from this cytokine-regulated shift in monocyte 
polarization, a cytokine-independent pathway has also been exposed, by which 
phagocytosis of MSCs caused monocytes to shift into a type 2 anti-inflammatory 
phenotype (109). Concerning dendritic cells, they seem to be less active in CD4+ 
T cell proliferation and to present an MHC class II-peptide complex. Moreover, in 
attendance of MSCs, type 1 dendritic cells secrete less TNF-α, while type 2 
dendritic cells increased IL-10 secretion (109). 
Additionally, MSCs were able to modulate the B cell response by paracrine actions 
(124, 125). MSCs are reported to decrease plasmablast formation of B cells as 
well as increasing the number of regulatory B cells (109). 
Next to MSCs, iPSC- or ESC-derived MSCs could also inhibit lymphocyte 





Figure 1.2. Mechanisms of action of stem cell-based therapies in cartilage 
regeneration and osteoarthritis (OA). First, stem cells could be applied as cell 
replacement therapy because of their chondrogenic differentiation potential. Differentiated 
mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) secrete 
proteoglycans (PGs) and collagen type II. Secondly, it is suggested that the tissue is 
regenerated by endogenous cells under the influence of paracrine factors secreted by stem 
cells. Extracellular vesicles (EVs) contribute to stem cell-mediated cartilage regeneration by 
promoting the formation of new cartilage and the deposition of collagen type II and 
glycosaminoglycans (GAGs). Finally, immunomodulatory effects are also observed. This 
image was created using Servier Medical Art, licensed under a Creative Common Attribution 
3.0 Generic License, available online at https://smart.servier.com/. 
1.3.3. Dental Pulp Stem Cells for Cartilage Regeneration and 
Osteoarthritis  
As previously mentioned, MSCs can be found in the stroma of any adult organ of 
the human body. Still, it remains to be elucidated which is the most suitable source 
of MSCs for the treatment of cartilage injuries or OA-associated lesions. Several 
subpopulations of MSCs can be distinguished within the human tooth and 
surrounding tissues (Figure 1.3), such as dental pulp stem cells (DPSCs) (130), 
stem cells from the apical papilla (SCAPs) (131), periodontal ligament stem cells 
(PDLSCs) (132), dental follicle precursor cells (DFPCs) (133) and tooth germ 
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progenitor cells (TGPCs) (134). Additionally, the gingiva contains other MSC 
subtypes; gingival MSCs (GMSCs) and the alveolar bone comprises alveolar bone-
derived MSCs (ABMSCs) (135, 136). In addition, stem cells from the pulp of 
human exfoliated deciduous teeth (SHEDs) and deciduous periodontal ligament 
(DePDL) can also be isolated (137, 138). Consequently, the human tooth can be 
considered as a treasured supply for MSCs. While all these MSC subpopulations 
hold great promise for cell-based regenerative applications, the present work, 
described in this dissertation, puts focus on DPSCs to hold promise for OA 
treatment and cartilage regeneration. 
 
Figure 1.3. Overview of all tooth-associated mesenchymal stem cell (MSC) types. 
Different sources of MSCs can be distinguished within the human tooth and surrounding 
tissues; dental pulp stem cells (DPSCs), stem cells from the apical papilla (SCAPs), 
periodontal ligament stem cells (PDLSCs), dental follicle precursor cells (DFPCs) and tooth 
germ progenitor cells (TGPCs). Additionally, two other MSC subtypes can be found in the 
gingiva and alveolar bone; gingival MSCs (GMSCs) and alveolar bone-derived MSCs 
(ABMSCs). In addition, stem cells from the pulp of human exfoliated deciduous teeth 
(SHEDs) can also be isolated. This image was adapted from Wang et al. (139). 
Gronthos et al. demonstrated the capacity of DPSCs to generate dentin both in 
vitro and in vivo (130). Therefore, DPSCs were initially considered for possible 
applications in regeneration of dental-associated tissues. Following reports 
revealed their MSC-like characteristics, including their immunophenotyping, 
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plastic adherence and the ability to differentiate into classical mesodermal cell 
lineages; adipocytes, osteocytes and chondrocytes in vitro (39, 92). In opposite 
to BM-MSCs, DPSCs showed a higher proliferative rate and have an easy isolation 
procedure by which they can be harvested (39). In addition, the 
immunomodulatory properties of DPSCs display their promise as cell-based 
therapies for immune and inflammation-related diseases (140-143). 
DPSCs have been described previously as a promising cell source for hyaline 
cartilage restoration. Mata and colleagues showed that differentiated DPSCs 
express collagen type II and aggrecan in vitro and, when cultured in alginate 
hydrogels and implanted in a rabbit model, DPSCs resulted in significant cartilage 
regeneration (144). Numerous scaffolds have been utilized to emphasize the 
chondrogenic differentiation capacity of DPSCs, including hydrogels containing 
poly(ethylene glycol) dimethacrylate (PEGDMA), methacrylated gelatin (GelMA), 
HA- (145) and chitosan‐based scaffolds (146). In addition, Dai et al. reported that 
costal chondrocytes combined with exogenous FGF-9 are suitable to supply 
chondro-inductive stimuli to DPSCs in vitro and in vivo (147). Rizk and colleagues 
showed that TGF-β3-transduced DPSCs express chondrogenic markers in vitro and 
when seeded on poly-l-lactic acid/polyethylene glycol (PLLA/PEG) electrospun 
fiber scaffolds in vivo (148). Chen et al. demonstrated the successful chondrogenic 
differentiation by SHEDs in vitro and the ability to generate new cartilage-like 
tissues after subcutaneous transplantation in nude mice (149). Yu and colleagues 
showed that the in vivo transplantation of rat STRO-1+ DPSCs at the 1st passage 
developed into dentin, bone and cartilage structures (150). Also paracrine-
mediated effects have been attributed to DPSCs for cartilage regeneration and 
beneficial effects in arthritis-related diseases. In an experimental mouse model of 
rheumatoid arthritis (RA), clinical assessment revealed minimal paw swelling after 
treatment with SHEDs (151). In dogs diagnosed with OA, multiple IA injections of 
puppy deciduous teeth stem cells (pDSCs) were performed. Their outcomes 
showed that IA injection considerably reduced pain and lameness, and prevented 
OA progression (152). In horses, equine dental pulp connective tissue particles 
showed a remarkable decrease in lameness for at least two weeks. Comfort scores 
were improved between, before, and 45 days after pulp injection (153).  
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Despite the fact that substantial reports put light on their chondro-regenerative 
capacities, data showing paracrine-mediated chondro-salvaging or protective 
effects of DPSCs are limited. Future investigations elucidating the DPSC-mediated 
effects by which they might aid in OA should therefore be implemented. 
1.4. Platelet Concentrates for Cartilage Regeneration and 
Osteoarthritis  
In articular cartilage, numerous growth factors act in synergy to control 
development and homeostasis of the tissue throughout life. Therefore, growth 
factors have been proposed as promising treatments for enhanced regeneration 
of cartilage or in inflammatory situations such as in OA. Different growth factors 
including TGF-β, basic (b) FGF, bone morphogenetic proteins (BMPs) and platelet 
derived growth factor (PDGF) have been described to have favourable effects on 
hyaline cartilage repair (reviewed in (154)). However, the administration of 
individual growth factors or cytokines has different disadvantages, including short 
time of activity, requiring the injection of massive amounts of growth factors, and 
multiple injections (155, 156). A growing amount of researchers are focusing on 
natural growth factor reservoirs, such as platelet concentrates. The usage of 
platelet concentrates is rising in different medical fields, because of their 
availability, cost-effectiveness, and their autologous nature (157). Moreover, 
nowadays, research in the tissue engineering field aims on the identification of 
useful scaffolds to address the requirements of adequate healing of large cartilage 
defects. Among biomaterials, gel-like platelet derivatives might reach particular 
attention.  
Platelet concentrates were already utilized decades ago; fibrin glue, for instance, 
was already used as a surgical additive in the 1970’s. During the years, several 
different techniques have been investigated and every technique resulted in a 
different platelet-derivative varying in growth factors secretion levels, leukocyte 
content and fibrin matrix. Platelet concentrates can be divided into first and 
second generation platelet concentrates (158).  
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1.4.1. First Generation Platelet Concentrates  
The first blood derivatives used were the fibrin glues or fibrin sealant. They are 
composed of concentrated fibrinogen, thrombin, and calcium chloride. Fibrin glues 
can be used as tissue adhesives for a variety of surgical procedures. Their 
widespread use has been hampered by their weakness compared to other sealants 
and the high costs associated to processing autologous blood. These drawbacks 
added to the development of platelet rich plasma (PRP), an autologous blood 
derivative, which combines the fibrin properties of fibrin sealants with the 
presence of platelets. PRP can be used as a liquid solution or as a gel and both 
forms have a low density fibrin network. Despite the wide variety of clinical 
applications, there are some disadvantages associated to PRP. The production 
requires the use anti-coagulants and the use of bovine thrombin. Moreover, there 
is a variety of available preparation protocols, which result in different end 
products without proper standardization (158, 159).  
1.4.2. Second Generation Platelet Concentrates  
Platelet-rich fibrin (PRF) is a second generation platelet concentrate. This group 
of platelet derivatives is made up by two subtypes: ‘pure platelet-rich fibrin (P-
PRF)’ without leukocytes and ‘leukocyte- and platelet-rich fibrin (L-PRF)’ with 
leukocytes. In contrast to PRP, the production of L-PRF does not require any 
biochemical handling and is generated by one single centrifugation step of whole 
blood without the supplementation of anti-coagulants. Table 1.1. offers an 
overview comparing L-PRF, to P-PRF and PRP about their most important 
properties (159, 160). L-PRF offers a simple and cost effective substitute to PRP. 
After centrifugation, three different parts can be distinguished: red blood cells at 
the bottom, an acellular plasma part and the L-PRF clot in the middle of the tube 
(158, 159). Despite the wide variety of clinical implementations, the present 
dissertation focusses on the chondrogenic potential of L-PRF (Figure 1.4).  
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Table 1.1. Overview table comparing L-PRF, P-PRF and PRP about their 
most important characteristics. 
 L-PRF P-PRF PRP 
Protocol Easy Complex Complex 
Speed-rate Fast Fast Slow 
Use of anti-coagulants No Yes Yes 
Costs Low High High 
Fibrin High High Low 
Polymerization Strong Strong Weak 
Presence of leukocytes High Poor Moderate 
Immunomodulation High Poor Poor 
Angiogenic effects High High Moderate 
Mechanical properties Strong Strong Moderate 
 
Figure 1.4. Schematic illustration of the pure platelet-rich fibrin (P-PRF) and 
leukocyte- and platelet-rich fibrin (L-PRF) architecture and the production 
protocol for L-PRF. (A-B) PRF can exist in two forms: P-PRF (A) and L-PRF (B). They can 
be distinguished based on the presence of leukocytes. Leukocytes are displayed as the blue 
larger circles, platelets are the light blue smaller structures and the fibrin network is 
visualised by the grey-orange thick structures. (C) One-step protocol for the generation of 
L-PRF. After collection of whole blood, tubes must be immediately centrifuged, which results 
in three layers; red blood cells, the L-PRF clot in the middle of the tube and an acellular 
plasma fraction. This image was created using Servier Medical Art, licensed under a Creative 
Common Attribution 3.0 Generic License, available online at https://smart.servier.com/. 
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1.4.3. The Chondrogenic Properties of Leukocyte- and Platelet-
Rich Fibrin  
L-PRF consists of three components: the leukocytes portion, platelets and the 
fibrin matrix, all of which can have a beneficial influence on cartilage regeneration 
or OA. The leukocytes present in L-PRF have an influence not only because of their 
immune potential but also because these cells are important mediators of the 
wound healing processes. Leukocytes can secrete various cytokines or growth 
factors, influencing chondrogenesis or inducing a positive effect on the underlying 
immunological process of OA. They have been reported to induce an 
overproduction of some growth factors, including vascular endothelial growth 
factor (VEGF) and TGF-β1 (161).  
Platelets are significant sources of growth factors and other biomolecules which 
can stimulate cartilage regeneration or induce proliferation and activation of other 
cells involved in the OA pathophysiology (162). Platelets contain three types of 
organelles: lysosomes, dense granules and alpha granules. These alpha granules 
contain platelet-specific proteins, cytokines, growth factors, angiogenic factors 
and PGs. Upon degranulation, platelets release various growth factors, which have 
also been reported to enhance tissue healing, cartilage homeostasis and 
immunomodulation (154, 163). These growth factors comprise; PDGF, IGF-1, 
TGF-β1, bFGF, epidermal growth factor (EGF) and VEGF, all that have been 
described to positively influence chondrogenesis and chondrocytes (164).  
The third component of L-PRF is the fibrin matrix. This matrix does not only 
capture the factors released by the platelets and leukocytes, which offers a slow 
release over time, but it also offers a suitable scaffold during tissue regeneration. 
Therefore, when it comes to healing of a cartilage defect, the fibrin matrix might 
be of particular interest.  
To date, numerous studies have mainly investigated the cartilage regenerative 
potential of other platelet derivatives, such as PRP (165). In vitro studies 
demonstrated their positive effects on chondrocyte proliferation and deposition of 
cartilage matrix (166, 167). Several preclinical animal studies revealed positive 
effects on cartilage repair induced by PRP (168). In vitro studies of the 
chondrogenic potential of L-PRF are limited (164). Some trophic and protective 
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effects by PRF on chondrocytes have previously been demonstrated (169-171), 
and one in vitro study showed the chondro-inductive effect of the eluate from 
fibrin-rich plasma membrane on AT-MSCs (172). L-PRF was also tested in 
preclinical animal studies for cartilage repair by several previously. The platelet 
concentrate was tested for repair of chondral, osteochondral and menisci defects 
in mainly rabbit and dog models. Overall, preclinical studies demonstrated 
promise for cartilage repair after PRF treatment was combined with autologous 
cartilage or MSCs (164). However, little is known about the mechanisms of action 
and biological features of L-PRF on chondrogenesis and on chondrocytes. 
1.5. Tendon Injuries  
1.5.1. Pathophysiology and Current Treatments  
Tendons function in transmitting forces from skeletal muscle to bone as well as 
providing stability to the joint (173). Tendon injuries are a common clinical matter 
in both human and veterinary medicine. Tendon development depends on the 
interplay of growth factors, transcription factors and tension during development. 
Tendons are primarily made up of collagen with tenocytes residing in between the 
fibres. 70% of the tendon is water, while 30% is dry mass, of which collagen type 
I accounts for 65-80%, and elastin for approximately 2%. Tendon is not only 
made up of type I collagen but, to a lesser extent, also other collagens, such as 
collagen type III, IV, V, and VI, are present. The ECM is composed of several PGs, 
glycoproteins, and other smaller molecules (173, 174). Decorin and biglycan are 
PGs and function in the organisation of collagen fibre bundles. Other tendon-
associated PGs include fibromodulin and lumican. Tenascin C is a glycoprotein, 
which is regulated by mechanical stimulation and is key in collagen fibre alignment 
and orientation. Another tendon-related glycoprotein is tenomodulin, which is 
crucial in proliferation and maturation of tendon cells. The expression of 
tenomodulin is positively regulated by scleraxis. Scleraxis, together with Mohawk, 
and early growth response protein 1 have been recognised as crucial transcription 
factors involved in the development of tendon tissue (175).  
Current treatment strategies are inadequate in restoring the function the tissue 
exerted before. They consist out of nonsteroidal anti-inflammatory drug injection, 
physiotherapy, or surgery (10, 174). Tendon tissue engineering has been 
Chapter 1 
20 
proposed as a promising technique for tendon repair. MSCs, including tendon-
derived stem cells (TDSCs), have been widely studied in tendon regenerative 
fields, because of their prominent differentiation capacity, expression of tendon 
markers, and remarkable self-renewal ability (176). Although many genes are 
reported to be involved in tendon development, they are not solely expressed in 
tendon tissues. Moreover, because of this limited knowledge in tendon-specific 
markers, transcription factors and signalling pathways, there is a lack of a 
standardized method for tenogenic differentiation (176).  
1.6. In Vitro Evidence of Tenogenic Differentiation of Stem 
Cells  
In contrast to chondrogenic, adipogenic, and osteogenic differentiation systems, 
there is no adequate tenogenic differentiation method. Several growth factors 
associated with tendon development, namely endothelial growth factor, VEGF, 
bFGF, PDGF, and TGF-β, have been utilized to drive MSCs towards the tenogenic 
lineage. In addition to growth factors, mechanically loaded cultures and various 
scaffolds have been widely employed to study tenogenesis by MSC subtypes 
(177). Moreover, co-culture systems between MSCs and TDSCs have also been 
applied (175, 176). However, studies investigating the combined effect of growth 
factors and 3D culture, and the combination with tension or mechanical 
stimulation, are paving the way towards increased knowledge of differentiating 
MSCs into the tenogenic lineage and contributes to the knowledge on the ideal 
MSC source for tendon-regenerative applications. The most investigated MSC 
subtypes include BM-MSCs, AT-MSCs and TDSCs.  
BM-MSCs are known to express several tendon-associated markers, such as 
tenascin C and collagen type I (178). Co-culture models with TDSCs demonstrated 
a crosstalk between both cell types to induce a tenogenic phenotype via the 
upregulation of tenogenic markers (179, 180). BM-MSCs have been demonstrated 
to form 3D embryonic tendon-like tissue in vitro via the usage of fixed-length 
fibrin gels and TGF-β3 signalling (181). Furthermore, paracrine-mediated impacts 
on tendon cells have also been investigated in vitro and in vivo (182). However, 
ectopic ossification is one of the major drawbacks of utilizing BM-MSCs for soft-
tissue regeneration (183). In attempt to overcome this, AT-MSCs established an 
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interesting candidate cell source for tendon tissue engineering. They can be 
isolated from subcutaneous adipose tissue or from liposuction aspirates (184, 
185). Comparable to BM-MSCs, co-culture models established a cellular crosstalk 
leading to an up-regulation of tendon-related markers (186). Tenogenic 
differentiation of AT-MSCs has been described upon stimulation by different 
growth factors in monolayer, (dynamic) scaffold cultures, mechanically loaded 
systems or variations in oxygen tension (187-190). In addition, they have been 
described to aid in tendon repair via the prevention of ectopic bone formation, 
inhibition of inflammation and stimulation of vascularisation (191). Nevertheless, 
AT-MSCs isolation might produce inhomogeneous cell populations.  
TDSCs compose up to 3-4% of the total number of cells in tendons and have been 
reported to be able to differentiate towards tenocytes (176, 178). Several reports 
highlighted the possible contribution of tendon stem cell populations toward the 
generation of tendon-like tissues in vitro and in vivo, but the mechanisms involved 
are still to be fully understood (192, 193). Nonetheless, several drawbacks can be 
associated with the usage of TDSCs, such as limited cell numbers, donor-site 
morbidity and the purity of tendon cell populations is highly arguable (194).  
1.6.1. Dental Stem Cells for Tendon Regeneration  
MSCs derived from the dental pulp or periodontal ligament propose alternative 
stem cell sources for applications in tendon tissue engineering (195, 196). They 
are of particular interest compared to other MSC sources because of their easy 
isolation, a higher proliferative ability and immunomodulatory nature, as 
previously mentioned (39, 130, 197, 198). Several research groups demonstrated 
that periodontal ligament contains endogenous stem/progenitor cells (132, 199, 
200), which express tendon-specific markers such as scleraxis, tenomodulin and 
tenascin C (132, 201, 202). Tenogenic characteristics of PDLSCs in vitro upon 
growth factor stimulation, including FGF-2, TGF-β1 and BMPs were investigated 
previously. In vitro data indicated that both FGF-2 and growth/differentiation 
factor (GDF)-5 predominantly differentiate PDLSCs into teno/ligamentogenic 
lineages (196, 203, 204). Also, DPSCs are shown to express tendon-related 
markers such as scleraxis, tenascin C, tenomodulin, eye absent homologue (EYA) 
2, collagen type I and type VI under static mechanical loading and might be a 
potential cell source for tendon tissue engineering (195). Nevertheless, 
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investigating the tenogenic characteristics of PDLSCs in a 3D environment, and 
comparing them to DPSCs has never been considered so far.  
1.7. Aim of the Study  
Degenerative diseases and overloading of the joint may harm articular cartilage, 
eventually leading to OA, and can damage tendon tissue. These tissues are 
characterized by a limited intrinsic healing capacity and current treatment 
strategies do not restore full function of the tissue. As the number of patients 
suffering from OA and tendinopathies are cumulating, there is an increasing need 
for the development of new treatment strategies for articular cartilage defects, 
OA, and tendon lesions.  
Given the encouraging results of MSCs and platelet derivatives in (pre)clinical 
research and experimental evidence supporting their therapeutic potential in OA 
and cartilage repair, a first part of the study focused on gaining more insights on 
MSC- and platelet concentrate-based therapies for cartilage repair and OA. In 
contrast to BM-MSCs, DPSCs are a less studied MSC subtype in the field of 
cartilage regeneration and OA management. Nevertheless, they own superior 
properties to BM-MSCs and can be obtained with minimal invasive surgical 
procedures and donor site morbidity. Moreover, in vitro studies of the 
chondrogenic potential of L-PRF are limited, as most research focused on PRP 
within the field of cartilage regeneration. Because of the chondrogenic 
differentiation potential and immunomodulatory properties of DPSCs, and the 
growth factor-rich content of L-PRF, we hypothesize that DPSCs and L-PRF 
can both enhance cartilage regeneration in vitro and have 
immunomodulatory effects (Figure 1.5). In Chapter 2 of the current 
dissertation, we show the in vitro chondrogenic differentiation potential of human 
DPSCs compared to human BM-MSCs. Moreover, we evaluated whether L-PRF had 
an additive effect on chondrogenesis of both MSC types in a 3D cell-culture 
system. Secondly, we also assessed the effect of growth factor release of DPSCs 
and L-PRF on healthy chondrocytes and TNF-α- and IL-1β-stimulated 
chondrocytes in vitro, on viability, OA-related gene expression, cartilage-specific 
ECM deposition, and inflammatory cytokine secretion.  
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In a second part of the current dissertation, we focused on assessing the tendon-
regenerative capacities of two tooth-associated stem cell types. In Chapter 3, 
we evaluate the tenogenic differentiation capacity of DPSCs and PDLSCs 
and compare them to BM-MSCs. We hypothesized that PDLSCs provide a 
more unique and favourable MSC source over DPSCs and BM-MSCs to 
synthetize tendon-like constructs in vitro. 3D growth conditions under static 
tension and the exogenous supplementation of TGF-β3 are investigated to 
generate tendon-like structures in vitro. Cell alignment, cell density, gel 
contraction and the presence of tendon-related markers were assessed (Figure 
1.5).  
Before DPSC or L-PRF treatment approaches might be implemented into the clinic, 
preclinical studies requiring translational large animal models are needed. In 
Chapter 4, we discuss the advantages and disadvantages of small and 
large animal models for translational cartilage repair studies. We also 
focused on suitable outcome measures for evaluating cartilage repair in 
preclinical studies.  
Preclinical studies in orthopaedic research for cartilage repair and in OA using the 
sheep as a large animal model are emerging. This is because of marked similarities 
of the sheep with human cartilage repair processes and joint organisation. Critical-
size defect and OA models have been described in the sheep, and data on ovine 
MSCs is currently also increasing. However, characterization of ovine MSCs is not 
fully known and caused some controversy. In Chapter 5, we aim to isolate 





Figure 1.5. Aim of the current dissertation. Osteoarthritis (OA) is a degenerative and 
inflammatory condition of synovial joints with irreversible loss of supportive cartilage matrix. 
Dental pulp stem cells (DPSCs) can be differentiated into cartilage-producing cells and 
secrete numerous growth factors associated with tissue repair and immunomodulation. 
Moreover, leukocyte- and platelet-rich fibrin (L-PRF), a blood-derived and clinically applied 
biomaterial, has recently emerged as a promising treatment in regenerative medicine due 
to its growth factor content and supportive fibrin matrix. Therefore, we hypothesize that 
DPSCs and L-PRF can both enhance (endogenous) cartilage regeneration in vitro and have 
paracrine-mediated effects. Other common MSDs are tendon-related pathologies. 
Spontaneous tendon healing results in the formation of a scar-like tissue with inferior 
structural and mechanical properties. In a second part of the current study, we focus on the 
tenogenic differentiation capacity of DPSCs and periodontal ligament stem cells (PDLSCs) 
and compare them to bone marrow-derived mesenchymal stem cells (BM-MSCs). Three-
dimensional (3D) growth conditions under static tension and the exogenous 
supplementation of transforming growth factor-beta 3 (TGF-β3) are investigated to 
synthetize tendon-like structures in vitro. This image was created using Servier Medical Art, 
licensed under a Creative Common Attribution 3.0 Generic License, available online at 
https://smart.servier.com/. 
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Osteoarthritis (OA) is a degenerative and inflammatory joint disorder with 
cartilage loss. Dental pulp stem cells (DPSCs) can undergo chondrogenic 
differentiation and secrete growth factors associated with tissue repair and 
immunomodulation. Leukocyte- and platelet-rich fibrin (L-PRF) emerges in 
regenerative medicine because of its growth factor content and fibrin matrix. This 
study evaluates the therapeutic application of DPSCs and L-PRF in OA via 
immunomodulation and cartilage regeneration. Chondrogenic differentiation of 
DPSCs, with or without L-PRF exudate (ex) and conditioned medium (CM), and of 
bone marrow-derived mesenchymal stem cells (BM-MSCs) was compared. These 
cells showed differential chondrogenesis. L-PRF was unable to increase cartilage-
associated components. Immature murine articular chondrocytes (iMACs) were 
cultured with L-PRF ex, L-PRF CM, or DPSC CM. L-PRF CM had pro-survival and 
proliferative effects on unstimulated and cytokine-stimulated iMACs. L-PRF CM 
stimulated the release of interleukin (IL)-6 and prostaglandin E2 (PGE2), and 
increased matrix metalloproteinase (MMP)-13, tissue inhibitor of 
metalloproteinase (TIMP)-1 and IL-6 mRNA levels in cytokine-stimulated iMACs. 
DPSC CM increased the survival and proliferation of unstimulated iMACs. In 
cytokine-stimulated iMACs, DPSC CM increased TIMP-1 gene expression, whereas 
it inhibited nitrite release in three-dimensional (3D) culture. We showed promising 
effects of DPSCs in an in vitro OA model, as they undergo chondrogenesis in vitro, 
stimulate the survival of chondrocytes and have immunomodulatory effects. 
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2.2. Introduction  
Articular cartilage plays key roles in the function of diarthrodial (synovial) joints 
(4, 6). Cartilage injuries are very common, predominantly in young and active 
athletes, and particularly in the knee joint (205-207). They are often considered 
as risk factors for the development of osteoarthritis (OA) in later life, a 
degenerative and inflammatory condition of the synovial joint with irreversible 
cartilage loss (6). OA results in disability, particularly in elderly people, and is 
associated with a large socio-economic burden (208, 209). OA is more prevalent 
in the female population and increases with age (209). In people over 60 years of 
age, it is estimated that 9.6% of men and 18% of women have symptomatic OA 
(210). Unfortunately, long-lasting regeneration of damaged articular cartilage 
remains an unmet clinical need. Current treatment strategies aim to relieve pain 
and clinical signs associated with inflammation. However, patients show no long-
term improvements (23). With the aim to restore the damaged cartilage tissue, 
matrix-induced autologous chondrocyte implantation (MACI), a Food and Drug 
Administration (FDA)-approved technique, has been developed (211). However, 
there are several disadvantages such as iatrogenic damage and high costs (25, 
212, 213). To overcome these problems, the use of innovative autologous 
biological tissue engineering techniques using stem cells forms an area of large 
interest in an attempt to achieve articular cartilage regeneration.  
Previous preclinical studies focused on the use of induced pluripotent stem cells 
(iPSCs) and mesenchymal stem cells (MSCs) to repair articular cartilage, 
demonstrating beneficial effects mediated via different mechanisms (as previously 
reviewed by our group (6)). However, because of the ethical implications 
regarding the usage of iPSCs and the invasive nature of bone marrow-derived 
mesenchymal stem cell (BM-MSC) isolation, an alternative cell source is of 
particular interest: dental pulp stem cells (DPSCs) originating from the neural 
crest-derived mesenchyme residing in the dental pulp (214, 215). Since they are 
isolated from extracted human third molars, DPSCs can be obtained with minimal 
donor site morbidity and iatrogenic damage. DPSCs have been classified as MSCs 
based upon the International Society for Cellular Therapy (ISCT) criteria (216). 
Apart from the opportunity of DPSCs to provide a cell replacement treatment, they 
show therapeutic potential in OA through paracrine and trophic influences on 
Chapter 2 
28 
endogenous cells. Current evidence indicates that DPSCs can be differentiated into 
cartilage-producing cells (39) and secrete numerous growth factors associated 
with tissue repair and immunomodulation, including vascular endothelial growth 
factor (VEGF), monocyte chemoattractant protein (MCP)-1, transforming growth 
factor-beta (TGF-β) and tissue inhibitors of metalloproteinase (TIMPs) (217-219). 
In addition, their immunomodulatory capacity makes them strong contenders to 
be used in inflammatory disorders (143), such as OA. Interestingly, intra-articular 
(IA) injection of DPSCs resulted in anti-inflammatory effects in rheumatoid 
arthritis (RA) (151). Co-culture of costal chondrocytes and DPSCs combined with 
fibroblast growth factors (FGF)-9 showed enhanced chondrogenesis and reduced 
ossification in tissue-engineered cartilage (147). However, until now, no 
chondrocyte-salvaging or -stimulating properties have been attributed to DPSCs.  
In addition, different growth factors including TGF-β, basic (b) FGF, VEGF, bone 
morphogenetic proteins (BMPs) and platelet derived growth factor (PDGF) have 
been described to have a beneficial effect on hyaline cartilage repair (154). 
Platelets are a natural reservoir of such growth factors within the human body 
(220). Platelet concentrates such as platelet-rich plasma (PRP) and leukocyte- and 
platelet-rich fibrin (L-PRF), are known to produce a plethora of autologous growth 
factors and cytokines (159). In recent years, first generation platelet-rich 
biomaterials such as autologous PRP have been widely studied in order to realise 
articular cartilage repair (168). In vitro studies demonstrated their positive effects 
on chondrocyte proliferation and deposition of cartilage matrix (166, 167). Several 
preclinical animal studies revealed positive effects on cartilage repair induced by 
PRP (168). In contrast to PRP, L-PRF is a second generation platelet concentrate 
which can be produced rapidly by the collection of autologous blood after one 
single centrifugation step and without anti-coagulants (158, 159). The generated 
product is a fibrin clot consisting of three components; leukocytes, platelets and 
a supportive fibrin matrix (221). Leukocytes and platelets progressively release a 
high concentration of cytokines and growth factors respectively over time (221, 
222). L-PRF might be applied in cartilage engineering studies because of its 
supportive fibrin matrix, while the leukocytes present in L-PRF might be important 
in immunomodulatory mechanisms via cytokine secretion. To date, numerous 
studies have mainly investigated the cartilage regenerative potential of other 
platelet derivatives, such as PRP (165). In vitro studies of the chondrogenic 
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potential of L-PRF are limited (164). Some trophic and protective effects by PRF 
on chondrocytes have previously been demonstrated (169-171), and one in vitro 
study showed the chondro-inductive effect of the eluate from fibrin-rich plasma 
membrane on a stem cell population (172). 
Because of the chondrogenic differentiation potential and immunomodulatory 
properties of DPSCs, and the growth factor-rich content of L-PRF, we hypothesise 
that DPSCs and L-PRF can both enhance cartilage regeneration in vitro and have 
immunomodulatory effects. In the current study, first, we investigated the in vitro 
chondrogenic differentiation potential of human DPSCs compared to human BM-
MSCs. Second, we evaluated whether L-PRF had an additive effect on 
chondrogenic differentiation of both MSC types in a three-dimensional (3D) cell-
culture system. Third, we assessed the effect of growth factor release of DPSCs 
and L-PRF on healthy chondrocytes and tumour necrosis factor-alpha (TNF-α) and 
interleukin-1beta (IL-1β)-stimulated chondrocytes in vitro, on viability, OA-
related gene expression, cartilage-specific extracellular matrix (ECM) deposition 




2.3. Materials and Methods  
2.3.1. Human Stem Cell Isolation and Culture 
Human third molars were obtained with written informed consent from patients 
(n = 16) of both genders (15-20 years of age) undergoing an extraction procedure 
for orthodontic reasons at Ziekenhuis Oost-Limburg (ZOL, Genk, Belgium). 
Written informed consent of minor patients was acquired via their custodians. The 
study was conducted in accordance with the Declaration of Helsinki, and the study 
protocol was approved by the medical ethical committee of Hasselt University 
(Belgium, protocol 13/0104U, date of approval 3 February 2014). The pulp tissue 
was obtained by means of forceps after mechanically fracturing the teeth. Next, 
the pulp tissues were minced into small pieces (1-2 mm³) and DPSCs were 
isolated via the explant method (39). Cells were maintained in minimal essential 
medium, alpha modification (αMEM, Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 100 U/mL Penicillin and 100 μg/mL Streptomycin (Sigma-
Aldrich), 2 mM l-glutamine (Sigma-Aldrich) containing 10% heat-inactivated 
foetal bovine serum (FBS) (Biowest, Nuaillé, France).  
BM-MSCs of three different donors (both male and female), between 6 and 12 
years old, were kindly provided by Prof. Dr. Cathérine Verfaillie (Stem Cell 
Institute, KU Leuven, Leuven, Belgium) (isolated from bone fragments (femur)). 
BM-MSCs were kept in high-glucose Dulbecco's modified Eagle’s medium (DMEM, 
Sigma-Aldrich) supplemented with 100 U/mL Penicillin and 100 μg/mL 
Streptomycin containing 10% heat-inactivated FBS. 
All stem cells were routinely screened in our lab for the expression of the following 
markers: CD34 (negative), CD44, CD45 (negative), CD90, CD105 and Stro-1 
(negative). Moreover, their trilineage differentiation capacity was evaluated as 
previously demonstrated by our group (39). All cell cultures were maintained at 
37 °C in a humidified atmosphere containing 5% CO2. The culture medium was 
changed every 2-3 days and all cultures were regularly monitored with an inverted 
phase-contrast microscope Nikon Eclipse TS100 (Nikon Co., Shinjuku, Tokyo, 
Japan) equipped with a Jenoptik ProgRes C3 camera (Jenoptik, Jena, Germany) 
with corresponding ProgRes Capture Pro 2.7 software. When reaching 80-90% 
confluence, cells were harvested using 0.05% trypsin/EDTA (Sigma-Aldrich) and 
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sub-cultured for further experiments. All experiments were conducted with DPSCs 
between passages 2 and 8. 
2.3.2. Isolation and Culture of Immature Murine Articular 
Chondrocytes 
Immature murine articular chondrocytes (iMACs) were isolated based upon a 
previously published protocol by Gosset et al. (223) and according to the animal 
welfare guidelines of the ethical committee of Hasselt University (ID 201762K, 
date of approval 11 November 2017). In short, after euthanasia of 5-6-day-old 
C57BL/6 wild type mice (n = 219), femoral heads, femoral condyles and tibial 
plateaus were isolated from the hind limbs and placed in phosphate buffered saline 
(PBS, Lonza, Basel, Switzerland). Isolated cartilage pieces were then incubated 
twice in 3 mg/mL collagenase D (Sigma-Aldrich) in low glucose DMEM (Sigma-
Aldrich) supplemented with 50 U/mL Penicillin, 50 μg/mL Streptomycin and 2 mM 
l-glutamine (iMAC standard culture medium) for 45 minutes at 37 °C in 5% CO2. 
Cartilage pieces were then incubated 0.5 mg/mL collagenase D in iMAC standard 
culture medium overnight at 37 °C in 5% CO2. Afterwards, cartilage fragments 
were passed through 25 mL, 10 mL, 5 mL and 2 mL pipettes to disperse any cell 
aggregates. After passing through a 70-μm cell strainer, the cells were centrifuged 
at 400 × g for 10 min. Cells were resuspended in iMAC standard culture medium 
supplemented with 10 % heat-inactivated FBS.  
Phenotypic characterization was performed by means of immunocytochemistry 
(ICC) and histological staining. In short, 26.32 × 10³ cells/cm² were seeded on 
glass or plastic (Thermanox®; Electron Microscopy Sciences, Hatfield, PA, USA) 
cover slips for 96 h in iMAC standard culture medium supplemented with 10% 
FBS. Afterwards, they were fixed using 4% paraformaldehyde (PFA) for 20 
minutes for ICC or using 2% glutaraldehyde in 0.05 M cacodylate buffer (pH 7.3) 
at 4 °C for transmission electron microscopy (TEM) processing. Immune-reactivity 
for collagen type II was demonstrated by ICC. Culture purity was assessed by 
determining the fraction of collagen type 2-positive cells using ImageJ software 
(The National Institute of Health, MD, USA). The presence of proteoglycans (PGs) 
was demonstrated via alcian blue, toluidine blue and safranin O staining. All 
experiments were performed with freshly isolated iMACs. 
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2.3.3. L-PRF Isolation 
Blood samples were obtained from 11 healthy donors from both genders (aged 
23-37) (n = 11) with written informed consent. The study protocol and consent 
procedure were approved by the medical ethical committee from Hasselt 
University and the Clinical Trial Centre from KU Leuven (S58789/B322201628215, 
date of approval 21 March 2016). All experiments were performed in accordance 
with relevant guidelines and regulations. Blood samples were drawn by 
venipuncture and collected in glass-coated plastic tubes (VACUETTE 9 ml Z Serum 
Clot Activator Tubes, Greiner Bio-One, Vilvoorde, Belgium). Samples were 
immediately centrifuged for 12 minutes at 2700 rpm (400 × g) (IntraSpinTM 
Centrifuge, Intra-Lock, Boca Raton, FL, USA) (Tubes were put per two into the 
centrifuge directly after drawing blood). The L-PRF clots were removed from the 
tubes using sterile forceps and separated from the red blood cell phase with an 
iris spatula (Fine Science Tools, Heidelberg, Germany) (Figure 2.1).  
 
Figure 2.1. Single step production protocol for leukocyte- and platelet-rich fibrin 
(L-PRF) and the generation of L-PRF conditioned medium (CM) and L-PRF exudate 
(ex). After collection, whole blood is immediately centrifuged (400 × g) for 12 min, resulting 
in three different compartments within the tube: red blood cells at the base, the L-PRF clot 
in the middle of the tube and an acellular plasma portion on top. For the generation of L-
PRF CM, L-PRF clots are placed in medium for 96 h. Afterwards, the medium is collected, 
centrifuged and stored until further use. For L-PRF ex collection, the L-PRF clots are put to 
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a sterile box and compressed, thereby releasing the exudate, which is collected and stored 
until further usage. This image was created using Servier Medical Art, licensed under a 
Creative Common Attribution 3.0 Generic License, available online at 
https://smart.servier.com/. 
2.3.4. L-PRF Conditioned Medium and Exudate  
For the production of L-PRF conditioned medium (L-PRF CM), L-PRF clots were 
placed in 6 ml of serum-free low glucose DMEM or DMEM/F12 (Thermo Fisher 
Scientific, Erembodegem, Belgium) supplemented with 2 mM L-glutamine, 50 or 
100  U/mL Penicillin and 50 or 100  μg/mL Streptomycin. After 96 h, the medium 
was collected, centrifuged for 6 minutes at 300 × g, sterile filtered (0.2 µm, 
Sarstedt, Nümbrecht, Germany) and stored at -80 °C until further use. For L-PRF 
exudate (L-PRF ex) collection, the L-PRF clots were brought to a sterile box 
(Xpression™ Fabrication Box, Intra-Lock) and compressed. The weighted press of 
the box converted the L-PRF clot into a membrane and the exudate was released 
from the clot, which was collected, sterile filtered and stored at -80 °C until further 
usage (Figure 2.1). 
2.3.5. Chondrogenic Differentiation 
Chondrogenic differentiation of DPSCs and BM-MSCs was induced according to the 
manufacturer’s instructions (StemXVivo Human/Mouse Chondrogenic 
Supplement, R&D systems, BioTechne, Minneapolis, MN, USA). A pellet containing 
2.5 × 105 cells in a 15 mL conical tube was subjected to chondrogenic 
differentiation medium consisting of DMEM/F12 supplemented with 1% insulin 
transferrin selenite (R&D systems) and 1% chondrogenic supplement (R&D 
systems). This supplement consists of dexamethasone, ascorbate-phosphate, 
proline, pyruvate and TGF-β3 with concentrations determined and validated by 
the manufacturer. To determine the effect of L-PRF on the chondrogenic 
differentiation, L-PRF ex (3%) and L-PRF CM (5% and 25%) were added to the 
differentiation medium. Positive and negative controls contained standard 
differentiation medium with or without the chondrogenic supplement respectively. 
Every 2-3 days, the medium was changed. The cells were allowed to differentiate 
for 21, 28 or 35 days, after which the pellets were either fixed with 4% PFA for 
immunohistochemical (IHC) analysis or with 2% glutaraldehyde in 0.05 M 
cacodylate buffer (pH 7.3) at 4 °C for TEM processing. Percentage alcian blue and 
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aggrecan stained area was quantified using Image J (The National Institute of 
Health, MD, USA).  
2.3.6. DPSC Conditioned Medium 
Conditioned medium of DPSCs (DPSC CM) was prepared by seeding human DPSCs 
at a density of 20 × 103 cells/cm² in iMAC standard culture medium supplemented 
with 10% FBS. Cells were allowed to attach overnight. Afterwards, cells were 
rinsed twice with PBS and 1 mL/5 cm² iMAC serum-free standard culturing 
medium was added. 48 h later, the medium was collected, centrifuged at 161 × 
g for 6 minutes and stored at -80 °C. 
2.3.7. Cell Survival and Proliferation Assay 
iMACs were seeded in triplicate in flat bottom 96 well plates at a density of 19.69 
× 10³ cells/cm² or 29.41 × 10³ cells/cm² for survival and proliferation assays 
respectively and were allowed to attach overnight. Hereafter, cells were washed 
twice with PBS and culture medium supplemented with L-PRF ex (1%, 3%, 5%), 
L-PRF CM (5%, 25%, 50%), or DPSC CM was added. For survival assays, the cells 
were cultured in serum-free conditions. For proliferation assays, experimental 
conditions were supplemented with 2% FBS. Negative and positive controls 
consisted of iMACs cultured in serum-deprived medium (0% or 2% for survival 
and proliferation respectively) or medium supplemented with 10% FBS 
respectively.  
For cytokine-stimulated iMACs, cells were seeded at a density of 29.41 × 10³ 
cells/cm2 and were allowed to adhere overnight. Subsequently, cells were washed 
twice with PBS and stimulated with the inflammatory cytokines recombinant 
mouse TNF-α (10 ng/mL) and recombinant mouse IL-1β (10 ng/mL) 
(Immunotools, Friesoythe, Germany) for 24 h. Hereafter, experimental conditions 
were added, including inflammatory cytokines TNF-α and IL-1β (10 ng/mL). 
Unstimulated conditions received no cytokines.  
The effect of L-PRF ex, L-PRF CM and DPSC CM on iMAC viability was evaluated 
using propidium iodide (PI, Sigma-Aldrich). After 24, 48, or 72 h, cells were lysed 
using Reagent A100 (Chemometec, Lillerød, Denmark). Next, cells were incubated 
with PI (diluted 1/50 in Reagent B (Chemometec)) for 15 minutes in the dark. 
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Solutions were transferred to a black 96-well plate with clear bottom (Greiner bio-
one) and fluorescence intensity was measured at an excitation wavelength of 540 
nm and an emission wavelength of 612 nm (FLUOstar OPTIMA, BMG Labtech, 
Ortenberg, Germany). 
2.3.8. Reverse Transcriptase Quantitative Polymerase Chain 
Reaction  
iMACs were seeded at a cell density of 52.63 × 10³ cells/cm² and left to adhere 
overnight. The cells were subsequently washed twice with PBS and stimulated 
with inflammatory cytokines recombinant mouse TNF-α (10 ng/mL) and 
recombinant mouse IL-1β (10 ng/mL) for 24 h. Afterwards, experimental 
conditions were added containing TNF-α and IL-1β (10 ng/mL). Unstimulated 
conditions received no cytokines. All cells were cultured in 2% FBS.  
After 24 h, medium was collected, centrifuged and stored at −80 °C for enzyme-
linked immunosorbent assay (ELISA) experiments, while RNA was extracted from 
total cell lysates using the RNeasy Mini Kit (74104, Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s instructions. After reverse 
transcription to cDNA using qScript cDNA Supermix (Quanta Bioscience, Carlsbad, 
CA, USA), a quantitative PCR was conducted on a StepOnePlus detection system 
(Applied Biosystems, Foster City, CA, USA) using standardised cycling conditions 
(20 s at 95 °C, 40 cycles of 3 s at 95 °C and 30 s at 60 °C). Primer sequences are 
listed in Table 2.1. 
Table 2.1. The primers used for reverse transcriptase quantitative 
polymerase chain reaction  analysis. 














































































2.3.9. Enzyme-Linked Immunosorbent Assay  
ELISAs were performed for IL-6 and prostaglandin E2 (PGE2) (R&D systems). 
ELISAs were performed according to the guidelines of the manufacturer. The 
absorbance of the end product was measured with a plate reader (FLUOstar 
OPTIMA and iMARK Microplate Reader, Biorad, Temse, Belgium). To ensure that 
the measured concentrations in L-PRF ex, L-PRF CM and DPSC CM were iMAC-
derived, the conditions were included in the ELISA experiment as a control. 
2.3.10. Nitrite Measurements  
iMACs were seeded at a density of 52.63 × 10³ cells/cm² and were allowed to 
adhere for 24 h. Cells were subsequently washed twice met PBS and stimulated 
with the inflammatory cytokines TNF-α (10 ng/mL) and IL-1β (10 ng/mL). After 
24 h, experimental conditions were added containing TNF-α and IL-1β (10 ng/mL). 
Unstimulated conditions received no cytokines. All cells were cultured in 2% FBS. 
After another 24 h, the medium was collected, centrifuged and stored at −80 °C.  
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Nitrite was quantified using the Griess Reagent System (Promega Benelux B.V., 
Leiden, The Netherlands) according to the manufacturer’s guidelines. Absorbance 
was measured at a wavelength of 540 nm using a plate reader (FLUOstar 
OPTIMA). 
2.3.11. Three-Dimensional Culture of iMACs 
For cytokine-stimulated iMAC pellets, 5 × 105 iMACs were washed twice and 
resuspended in culture medium containing recombinant mouse TNF-α (10 ng/mL) 
and recombinant mouse IL-1β (10 ng/mL). Cells were centrifuged in 15 ml 
polypropylene tubes at 400 × g and maintained at 37 °C under 5% CO2. The caps 
of the tubes were loosened to allow for air exchange. 24 h later, the medium was 
replaced for the experimental conditions with TNF-α and IL-1β (10 ng/mL). 
Unstimulated conditions received no cytokines. All conditions were cultured in 2% 
FBS. 72 h later, the medium was collected, centrifuged and stored at −80 °C for 
nitrite measurements, while pellets were fixed with 4% PFA for IHC.  
2.3.12. Transwell Migration Assay 
iMACs were seeded in 24 well plates in iMAC standard culturing medium at a 
density of 26.32 x 10³ cells/cm², and allowed to attach overnight. The day after, 
cells were washed with PBS and the medium was changed to serum-free standard 
culture medium. Positive and negative controls consisted of iMAC standard 
culturing medium supplemented with 10% or 0% FBS respectively. 24 h later, 
inserts (ThinCert™, 8  μm pore size, Greiner Bio-One) were coated with 0.01 
mg/ml poly-L-lysin (Sigma-Aldrich) for 1.5 h and washed with MilliQ and PBS. 
52.63 x 10³ cells/cm² DPSCs, suspended in iMAC standard culturing medium 
supplemented with 0% FBS, were seeded in the inserts. After 24  h, the 
transmigrated cells were fixed with 4% PFA and stained with 0.1% crystal violet. 
Migration was quantified with AxioVision software (Carl Zeiss, Aalen, Germany). 
2.3.13. Immunocytochemical Staining 
For collagen type II expression in iMACs, permeabilisation and blocking occurred 
simultaneously with 10% protein block (DAKO, Glostrup, Denmark) and 0.2% 
Triton in PBS for one hour. Cells were then incubated with a rabbit anti-collagen 
type II antibody (ab34712, polyclonal, 1:100, Abcam, Cambridge, UK) diluted in 
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10% protein block in PBS for one hour at room temperature (RT). Negative 
controls were included that were omitted of primary antibody. Afterwards, they 
were incubated with the Alexa 555-labelled donkey anti-rabbit IgG (A31572, 
Thermo Fisher Scientific) diluted 1/500 in PBS for 30 min. Nuclei were stained 
with 4′,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific) for 10 min. 
Samples were mounted using fluorescence mounting medium (DAKO). Pictures 




Cartilage pellets were embedded in paraffin and 7 μm thick sections were cut. 
Samples were deparaffinised in xylene and ethanol baths (xylene: 2 times 5 min, 
ethanol: 100%, 100%, 95%, 80%, 70%, 50%, 2 minutes each). Antigen retrieval 
was performed by heating the samples three times for 5 minutes in 1 × target 
retrieval solution (DAKO). In case of 3,3'-Diaminobenzidine (DAB, DAKO) staining, 
peroxidase block (DAKO) was used for 20 minutes. Next, nonspecific binding of 
the antibodies was inhibited with protein block (DAKO) for 30 minutes at RT. 
Samples were then incubated with a rabbit anti-aggrecan antibody (ab186414, 
clone number EPR14664, 1:500, Abcam) diluted in 10% protein block in PBS for 
one hour at RT. Subsequently, samples were incubated with the advance HRP Link 
System (K4067, DAKO) for 30 minutes at RT. Hereafter, samples were incubated 
with DAB for 5 minutes and counterstained with haematoxylin for 8 minutes after 
which they were washed with running tap water for 20 min. 
Histology 
For histological analyses routinely used safranin O, alcian blue, toluidine blue and 
Masson’s trichrome staining were performed.  
Safranin O 
Samples were incubated with haematoxylin for 8 minutes, and washed with 
running tap water for 20 minutes. Next, they were incubated with 0.05% Fast 
Green solution for 5 minutes and rinsed with 1% acetic acid solution for 10 
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seconds. Thereafter, the samples were incubated in 0.1% Safranin O solution 
(Merck, Overijse, Belgium) for 5 minutes.  
Alcian blue 
Samples were incubated with Alcian blue solution (pH = 2.5) for 30 minutes at 
room temperature (RT). Subsequently, samples were washed with running tap 
water for 10 minutes and submerged in distilled water for 1 minute. Next, nuclear 
fast red solution was applied for 10 minutes and samples were dipped for 1 second 
in distilled water.  
Toluidine blue 
Samples were incubated with 1% Toluidine blue solution for 20 minutes at RT. 
Subsequently, samples were washed with distilled water for 30 seconds.  
Masson’s trichrome 
After incubation with haematoxylin and running tap water, samples were 
incubated in Ponceau/Fuchsine solution for 5 minutes. Next, samples were 
incubated in 1% phosphomolybdic acid and Aniline blue solution for 5 minutes 
each. After incubation in 1% phosphomolybdic acid for 5 minutes, samples were 
placed in acetic acid for 2 minutes. Between each incubation, samples were 
washed with distilled water. 
All samples were dehydrated in ethanol and xylene (ethanol: 70%, 80%, 95%, 
100%, 100%, 100% xylene, 100% xylene, 2 minutes each) and mounted using 
DPX (Merck, Darmstadt, Germany). Slides were visualised with the Mirax slide 
scanner (Carl Zeiss NV-SA, Zaventem, Belgium) using the Mirax scan software. 
Photos of scanned slides were made with the Mirax viewer (Carl Zeiss NV-SA) or 
images were taken with a Leica DM2000 LED Microscope.  
2.3.15. Transmission Electron Microscopy  
Samples were processed for TEM imaging as described previously (224). After 
fixation, the fixative was aspirated with a glass pipette, and samples were 
postfixed in 2% osmium tetroxide for one hour. Subsequently, samples were 
placed through a dehydrating series of graded concentrations of acetone. 
Dehydrated samples were impregnated overnight in a 1:1 mixture of acetone and 
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araldite epoxy resin at RT. After impregnation, samples were embedded in araldite 
epoxy resin at 60 °C and monolayer samples were embedded in araldite according 
to the popoff method (225). Ultrathin sections (0.06 μm) were mounted on 0.7% 
formvar-coated copper grids (Aurion, Wageningen, the Netherlands), contrasted 
with 0.5% uranyl acetate and a stabilised solution of lead citrate using a Leica EM 
AC20 (Leica). Samples were observed using a Philips EM 208 transmission 
electron microscope (Philips, Eindhoven, The Netherlands) equipped with a 
Morada Soft Imaging System camera with corresponding iTEM-FEI software 
(Olympus SIS, Münster, Germany).  
2.3.16. Statistical Analysis 
Statistical analysis was performed using Graphpad Prism 7.04 software 
(Graphpad, San Diego, CA, USA). Normality was tested using the Shapiro-Wilk 
and the D’Agostino and Pearson normality test. Normal distributed data were 
tested with one-way analysis of variance (ANOVA) or two-way ANOVA and 
Dunnet’s multiple comparison post-test. Nonparametric data were analysed with 
the Kruskal-Wallis test followed by Dunn’s post-test. “n” represents the number 
of experiments (for every experiment a different DPSC/L-PRF donor was used). 
Any p-value ≤ 0.05 was considered to be statistically significant. All data were 
presented as mean ± standard error of mean (S.E.M.).  
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2.4. Results 
2.4.1. Differences in Chondrogenic Differentiation Potential 
Between BM-MSCs and DPSCs and the Effect of Exposure to 
L-PRF During Chondrogenesis  
In order to compare the chondrogenic differentiation potential between human 
DPSCs and BM-MSCs, cells were subjected to a 3D chondrogenic differentiation 
system over 21 days. To test the effect of exposure to L-PRF during chondrogenic 
differentiation, cells were subjected to the same 3D differentiation system, but 
supplemented with L-PRF ex (3%) or L-PRF CM (5% and 25%) for 21 days (n = 
3). Following the three week culture, both cell types formed compact 3D 
micromasses under all experimental conditions (Figure 2.2A). IHC revealed 
abundantly present ECM surrounding both differentiated stem cell types (Figure 
2.2A). Ultrastructural analyses of the 3D micropellets of both cell types showed 
the presence of dense matrix-filled vesicles, suggesting glycosaminoglycan (GAG) 
production (Figure 2.2B, arrowheads). This was supported by the alcian blue 
staining which demonstrated the presence of GAGs in the ECM of both 
differentiated MSC types (Figure 2.2C). Quantitative analysis of GAG production 
demonstrated no significant difference between DPSCs and BM-MSCs after 21 
days of differentiation (Figure 2.2D). Moreover, when the chondrogenic 
differentiation medium was supplemented with L-PRF ex or L-PRF CM, the 
percentage of the alcian blue-stained area in micropellets derived from both cell 
types was not significantly different (Figure 1D). Aggrecan expression could only 
be detected in differentiated BM-MSCs and remained absent in DPSC-derived 
pellets (Figure 2.2E, F). Likewise, when the differentiation period was extended to 
28 and 35 days, no aggrecan expression could be detected in micropellets derived 
from DPSCs (data not shown). Exposure to L-PRF ex or CM did not significantly 
augment the aggrecan expression in cartilage spheres derived from BM-MSCs 
(Figure 2.2F). The control pellet resulted in 36.69% ± 10.89% aggrecan-positive 
stained area, while 5% L-PRF CM caused 27.24% ± 16.22% aggrecan-positive 
area compared to 21.34% ± 4.61% aggrecan-stained area in BM-MSCs 




Figure 2.2. Differences in chondrogenic differentiation potential between human 
dental pulp stem cells (DPSCs) and human bone marrow-derived mesenchymal 
stem cells (BM-MSCs) and the effect of exposure to L-PRF during chondrogenesis. 
After 21 days of exposure to L-PRF ex (3%) or L-PRF conditioned medium (CM) (5% and 
25%), cartilage-specific protein expression in differentiated pellets was evaluated using 
(immuno)histological staining (n = 3). (A) Masson’s trichrome staining revealed the 
presence of abundant extracellular matrix (ECM) in micropellets derived from both 
differentiated stem cell types. (B) Ultrastructural analyses of the micropellets of both cell 
types showed the presence of dense matrix-filled vesicles (arrowheads). (C) 
Glycosaminoglycan (GAG) production was assessed by means of alcian blue staining. (D) L-
PRF ex or L-PRF CM stimulation did not enhance the GAG area percentage. (E) 
Immunohistochemical (IHC) revealed that aggrecan expression was present in differentiated 
BM-MSCs, but absent in the DPSC-derived pellets. (F) Aggrecan area percentage was not 
enhanced by L-PRF ex or L-PRF CM exposure. Scale bars A, C, E = 100 μm; B = 2 μm. Data 
in D and F are represented as mean ± S.E.M. 
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2.4.2. Phenotypical and Ultrastructural Characterization of 
Immature Murine Articular Chondrocytes   
iMACs were isolated from the femoral heads, femoral condyles and tibial plateau 
from hind limbs of 5–6-day-old wild type C57BL/6 mice. Phase contrast images 
revealed a rounded and polygonal morphology with a granular cytoplasm (Figure 
2.3A). Expression of the main markers of chondrocyte phenotype was assessed 
via (immuno)histology. Alcian blue and toluidine blue staining show the presence 
of PG components (Figure 2.3B, C), while ICC demonstrated collagen type II 
expression by iMACs (Figure 2.3D). The average culture purity was 93.24% ± 
1.33% (n = 3). Together, iMACs synthesise type II collagen and sulphated PGs in 
vitro after 4 days, showing the isolation of functional chondrocytes. 
Ultrastructurally, chondrocytes were characterised by a rounded, spherical 
morphology with ample rough endoplasmic reticulum, mitochondria and glycogen-
rich vacuoles (Figure 2.3E and insert).  
2.4.3. Effect of Secreted Factors of DPSCs and L-PRF on Healthy 
Chondrocyte Survival and Proliferation and Viability of TNF-
α- and IL-1β-Stimulated iMACs  
In order to evaluate the influence of L-PRF ex, L-PRF CM and DPSC CM on the 
viability of unstimulated or cytokine-stimulated iMACs, a PI test was employed at 
different time points (Figure 2.3F-K). After 24 h, serum deprivation decreased 
survival compared to iMACs cultured in high serum conditions (Figure 2.3F, I). 
This effect could not be prevented by supplementation of L-PRF ex to iMACs 
(Figure 2.3F). In contrast, the highest L-PRF CM concentrations (25% and 50%) 
had a significant pro-survival effect compared to the negative control condition 
and this was demonstrated to have a proliferative influence when serum was 
absent (139% ± 11.93% for 25% L-PRF CM and 120.2% ± 3.02% for 50% L-PRF 
CM) (Figure 2.3F). When 2% serum was supplemented, all L-PRF CM 
concentrations (5%, 25% and 50%) significantly increased iMAC proliferation at 
48 h and 72 h (Figure 2.3G). When iMACs were stimulated with TNF-α and IL-1β, 
25% and 50% L-PRF CM showed a statistically significant increased viability 
compared to the cytokine-stimulated negative control at 48 h and 72 h (177% ± 
39.51% and 183.7% ± 38.24% for 25% and 50% L-PRF CM respectively 
compared to 65.1% ± 17.4% for the stimulated negative control for 48 h, 196.4% 
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± 33.86% and 231.2% ± 45.66% for 25% and 50% L-PRF CM respectively 
compared to 53.41% ± 26.7% for the stimulated negative control at 72 h) (Figure 
2.3H). L-PRF ex did not exert any stimulating effects on proliferation or viability 
of neither unstimulated nor cytokine-stimulated iMACs. In serum-deficient 
conditions, DPSC CM significantly stimulated iMAC survival compared to the 
negative control (84.16% ± 12.06% compared to 49.08% ± 11.81%) after 24 h 
(Figure 2.3I). In 2% serum conditions, iMAC underwent a significant increased 
proliferation compared to the negative control after 48 h and 72 h when cultured 
in DPSC CM (Figure 2.3J). When cytokine-stimulation was implemented, iMAC 
viability followed an increasing trend when cultured in DPSC CM at every time 
point, although this effect was not significant (Figure 2.3K). 
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Figure 2.3. Phenotypic characterization of immature murine articular chondrocytes 
(iMACs) and the effect of L-PRF ex, L-PRF CM and DPSC CM on iMAC survival, 
proliferation and chondrocyte viability in TNF-α- and IL-1β-stimulated conditions. 
(A) Phase contrast micrographs of mouse iMACs show a rounded, polygonal morphology. 
(B-D) Histological staining revealed the production of sulphated PGs, while 
immunofluorescence staining demonstrated collagen type II expression. (E) Transmission 
electron microscopy (TEM) showed a rounded, spherical morphology with abundant rough 
endoplasmic reticulum, mitochondria and glycogen-rich (GL) vacuoles (insert). The effect of 
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the secretome of L-PRF and DPSCs on unstimulated iMAC survival, proliferation and 
cytokine-stimulated iMAC viability were evaluated by means of a PI assay (F-K). (F) 25% 
and 50% L-PRF CM had a significant pro-survival effect on iMACs after 24 h compared to 
the negative control (n = 5). (G) 5%, 25% and 50% L-PRF CM had a significant proliferative 
effect on iMACs after 48 h and 72 h compared to the negative control (n = 4). (H) 25% and 
50% L-PRF CM significantly increased the viability of TNF-α- and IL-1β-stimulated iMACs 
after 48 h and 72 h (n = 5 for 24 h, n = 6 for 48 h, n = 6 for 72 h). (I) DPSC CM had a 
significant pro-survival effect on iMACs after 24 h compared to the negative control (n = 8). 
(J) DPSC CM significantly increased the proliferation of iMACs after 48 h and 72 h (n = 7 for 
24 h, n = 8 for 48 h, n = 9 for 72 h). (K) TNF-α- and IL-1β-stimulated iMAC viability follows 
an increasing trend after exposure to DPSC CM, although not statistically significant. (n = 8 
for 24 h, n = 10 for 48 h, n = 8 for 72 h). Scale bars A, B, C and D = 50 μm. Scale bar E: 
5 μm (original magnification: 5,600). Data are represented as mean ± S.E.M. *. p ≤ 0.05. 
**. p ≤ 0.01. ***. p ≤ 0.001. ****. p ≤ 0.0001. 
2.4.4. Effect of Secreted Factors of DPSCs and L-PRF on 
chondrogenic mRNA Expression of Unstimulated iMACs 
Expression levels of chondrocyte-markers were investigated in unstimulated 
iMACs cultured with 3% L-PRF ex, 25% L-PRF CM and DPSC CM after 24 h (Figure 
2.4). Aggrecan mRNA levels were significantly decreased upon supplementation 
of 3% L-PRF ex and 25% L-PRF CM (Figure 2.4A). 25% L-PRF CM significantly 
decreased mRNA levels of collagen type II α 1 (Figure 2.4B). TGF-β mRNA levels 
were not significantly altered by L-PRF ex, L-PRF CM and DPSC CM (Figure 2.4C). 
Matrix metalloproteinase (MMP)-13 was significantly upregulated in iMACs 
cultured with 25% L-PRF CM compared to control (Figure 2.4D), while TIMP-1 
mRNA expression levels were significantly upregulated by the supplementation of 
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Figure 2.4. The effect of L-PRF ex, L-PRF CM and DPSC CM on chondrogenic genes 
of iMACs. Gene expression levels of chondrogenic markers were determined by RT-qPCR of 
unstimulated iMACs exposed to 3% L-PRF ex, 25% L-PRF CM and DPSC CM. (A-B) 25% L-
PRF CM significantly decreased expression levels of collagen type II α 1 and aggrecan, while 
3% L-PRF exudate only downregulated aggrecan expression levels. (C) TGF-β mRNA levels 
were not significantly altered by L-PRF ex, L-PRF CM and DPSC CM. (D) MMP-13 was 
significantly upregulated in iMACs cultured with 25% L-PRF CM compared to the control. (E) 
TIMP-1 mRNA expression levels were significantly upregulated by the supplementation of 
25% L-PRF CM and DPSC CM. Data correspond to n = 6 for L-PRF ex and L-PRF CM, and n 
= 7 for DPSC CM. Data are represented as mean ± S.E.M. *. p ≤ 0.05. **. p ≤ 0.01. ***. 
p ≤ 0.001. ****. p ≤ 0.0001. 
2.4.5. Effect of Secreted Factors of DPSCs and L-PRF on OA-
related mRNA Expression of Unstimulated and TNF-α- and IL-
1β-Stimulated iMACs 
After iMACs were cytokine stimulated for 24 h and cultured in experimental 
conditions for another 24 h, gene expression levels of OA-related markers 
aggrecan, collagen type II α 1, TGF-β, MMP-13, TIMP-1, a disintegrin and 
metalloproteinase (ADAM)-17, IL-6, TNF-α and inducible nitric oxide synthase 
(iNOS) were measured. As shown in Figure 2.5, reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) results showed that cytokine stimulation of 
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iMACs significantly decreased cartilage-specific mRNA levels, such as aggrecan 
and collagen type II α 1, compared to unstimulated iMACs after 24 h (Figure 2.5A, 
B). No significant increase in aggrecan or collagen type II α 1 could be observed 
when iMACs were cultured with 3% L-PRF ex, 25% L-PRF CM or DPSC CM (Figure 
2.5A, B). mRNA levels of TGF-β, a growth factor playing indispensable roles in 
cartilage integrity and homeostasis, were also measured using RT-qPCR and were 
not significantly altered (Figure 2.5C). TNF-α and IL-1β stimulation of iMACs 
increased mRNA levels of the chondrocyte maturation marker MMP-13 compared 
to unstimulated iMACs (Figure 2.5D). Moreover, 25% L-PRF CM significantly 
increased MMP-13 mRNA levels (Figure 2.5D), while TIMP-1 was significantly 
upregulated by the supplementation of pro-inflammatory cytokines combined with 
25% L-PRF CM and DPSC CM compared to the stimulated control after 24 h (Figure 
2.5E). ADAM-17 mRNA levels were significantly increased upon exposure to 
cytokines, but not altered by the supplementation of L-PRF ex, L-PRF CM or DPSC 
CM (Figure 2.5F). Cytokines with 25% L-PRF CM significantly amplified the IL-6 
mRNA levels compared to the stimulated control (Figure 2.5G). TNF-α and iNOS 
mRNA levels were significantly increased upon exposure to cytokines, and are not 
altered upon supplementation of L-PRF ex, L-PRF CM or DPSC CM (Figure 2.5H, 
I).  
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Figure 2.5. Effect of L-PRF ex, L-PRF CM and DPSC CM on TNF-α- and IL-1β- 
stimulated iMAC OA-related gene expression. Relative mRNA levels were determined 
by RT-qPCR of unstimulated and cytokine-stimulated iMACs exposed to 3% L-PRF ex, 25% 
L-PRF CM and DPSC CM. (A–B) Chondrocyte marker genes, aggrecan and collagen type II α 
1, were significantly downregulated by cytokine stimulation, but not significantly altered by 
L-PRF ex, L-PRF CM and DPSC CM. (C) TGF-β mRNA levels were not altered upon exposure 
to cytokines, nor in combination with L-PRF ex, L-PRF CM or DPSC CM. (D) MMP-13 was 
significantly upregulated after cytokine stimulation, while 25% L-PRF CM further increased 
MMP-13 mRNA levels compared to the stimulated control. (E) TIMP-1 was upregulated by 
the supplementation of pro-inflammatory cytokines combined with 25% L-PRF CM and DPSC 
CM. (F) ADAM-17 expression was significantly upregulated after cytokine stimulation but not 
altered after exposure to L-PRF ex, L-PRF CM and DPSC CM. (G) 25% L-PRF CM significantly 
augmented the IL-6 mRNA levels compared to the stimulated control. (H–I) TNF-α and iNOS 
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mRNA levels were upregulated upon exposure to cytokines, but not altered by the 
supplementation of L-PRF ex, L-PRF CM or DPSC CM. Data correspond to n = 6 for L-PRF ex 
and L-PRF CM and n = 7 for DPSC CM. Data are represented as mean ± S.E.M. *. p ≤ 0.05. 
**. p ≤ 0.01. ***. p ≤ 0.001. ****. p ≤ 0.0001. 
2.4.6. IL-6 and PGE2 Release Are Increased After 
Supplementation of Cytokines Combined With L-PRF CM  
The medium of iMACs cultured in 3% L-PRF ex and 25% L-PRF CM and DPSC CM 
was collected after 24  h and subjected to an ELISA for IL-6 and PGE2 (Figure 
2.6). Cytokine stimulation enhanced IL-6 production by iMACs, although not 
significantly, from 0 ng/mL for the unstimulated control to 6.31 ng/ml ± 1.65 
ng/mL for the stimulated control (Figure 2.6A). Of all experimental conditions, 
only 25% L-PRF CM significantly enhanced IL-6 secretion (Figure 2.6A). 
Stimulation with cytokines in combination with 25% L-PRF CM induced a 
significant increase in PGE2 release by iMACs (86 ng/mL ± 24.14 ng/mL for 
stimulated 25% L-PRF CM compared to 2.75 ng/mL ± 1.11 ng/mL for the 
stimulated control) (Figure 2.6B).  
 
Figure 2.6. IL-6 and PGE2 secretion of iMACs after exposure to inflammatory 
cytokines and L-PRF ex, L-PRF CM and DPSC CM, measured via ELISA. (A) IL-6 
release of iMACs is significantly increased after exposure to cytokine stimulation combined 
with 25% L-PRF CM. (B) Stimulation with cytokines in combination with 25% L-PRF CM 
induced a significant increase in PGE2 release by iMACs. Data correspond to n = 3. Data are 
represented as mean ± S.E.M. **. p ≤ 0.01. ***. p ≤ 0.001. 
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2.4.7. Nitrite Levels Are Increased Upon Cytokine Stimulation 
and Decreased by DPSC CM   
To evaluate the influence of secreted factors of L-PRF and DPSCs on iMAC nitrite 
secretion, a Griess assay was performed. iMACs secreted significant more nitrite 
when they were stimulated with TNF-α and IL-1β in monolayer and 3D pellet 
culture (Figure 2.7A, B). In monolayer, 25% L-PRF CM exerted a small decrease 
in the nitrite secretion from 30.09 μM ± 1.69 μM to 26.69 μM ± 1.13 μM (Figure 
2.7A). However, this effect was not significant. Also in pellet culture, L-PRF CM 
exerted a small not significant decrease in nitrite release by cytokine-stimulated 
iMACs. L-PRF ex did not decrease the nitrite secretion in cytokine-stimulated iMAC 
after 24 h in monolayer, nor after 72 h in pellet culture. CM of DPSCs induced a 
small, but not significant reduction in nitrite production of iMACs after 24 h from 
30.09 μM ± 1.69 μM to 26.33 μM ± 1.84 μM in monolayer (Figure 2.7A). 
Remarkably, DPSC CM significantly decreased nitrite secretion of iMACs in 
micromass culture from 30.25 μM ± 1.87 μM to 17.08 μM ± 2.42 μM (Figure 
2.7B).  
 
Figure 2.7. The effect of L-PRF ex, L-PRF CM and DPSC CM on TNF-α and IL-1β-
stimulated iMAC nitrite release. Nitrite production in iMACs cultured in monolayer (A) 
and micropellet (B) was measured via the Griess assay. (A) In monolayer culture, nitrite 
production was significantly increased upon cytokine stimulation but not significantly altered 
by exposure to L-PRF ex, L-PRF CM and DPSC CM after 24 h. (B) In 3D micropellets, DPSC 
CM significantly reduced nitrite release of iMACs after 72 h. Data correspond to n = 5 for L-
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PRF ex and L-PRF CM, n = 7 for DPSC CM (A), n = 6 for L-PRF ex, n = 7 for L-PRF CM and 
DPSC CM (B). Data are represented as mean ± S.E.M. *. p ≤ 0.05. ****. p ≤ 0.0001. 
2.4.8. Cartilage-Specific ECM Production of iMACs in 3D Culture 
After Exposure to L-PRF ex, L-PRF CM and DPSC CM 
To test the effect of secreted factors of L-PRF and DPSCs on the cartilage-matrix 
production of cytokine-stimulated iMACs, 5 × 105 iMACs cultured in micromasses 
were stimulated with TNF-α and IL-1β for 24 h. Afterwards, experimental 
conditions were added and 72 h later cell pellets were used for histological 
examination of the cartilaginous structure. Unstimulated iMAC pellets generated 
a typical cartilage-like tissue composed of chondrocytes in distinct lacunae 
surrounded by a dense PG-rich matrix as shown by representative images of alcian 
blue, toluidine blue and safranin O staining (Figure 2.8, arrowheads). However, 
pellets formed by cytokine-stimulated iMACs developed into a more fibrous tissue 
in which cartilage-lacunae were less evident and meaningfully decreased ECM and 
GAG production could be observed. This was revealed by an obvious decrease in 
alcian blue, toluidine blue and safranin O staining intensity (Figure 2.8). Cytokine-
stimulated iMACs cultured with 3% L-PRF ex, 25% L-PRF CM and DPSC CM 
attained slightly more typical cartilage-like lacunae and showed a weak tendency 
of improved ECM content and chondrocyte status compared to the cytokine-
stimulated control. A tendency to a higher alcian blue staining intensity could also 
be observed when cytokine-stimulated iMACs were cultured on L-PRF ex, L-PRF 
CM and DPSC CM.  
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Figure 2.8. TNF-α- and IL-1β-stimulated iMACs cultured in 3D pellets attenuated a 
more cartilage-like morphology after exposure to L-PRF ex, L-PRF CM and DPSC 
CM. Representative images showed that unstimulated iMAC pellets generated a cartilage-
like tissue with large numbers of chondrocytes present in lacunae (arrowheads). In the 
cytokine-stimulated control condition, iMACs developed into a more fibrous tissue in which 
cartilage-lacunae were less evident and GAG production is meaningfully reduced, as shown 
by an apparent decrease in alcian blue, toluidine blue and safranin O staining intensity. 
Cartilage lacunae were more preserved by L-PRF ex, L-PRF CM and DPSC CM with a weak 
tendency of improved ECM content and chondrocyte status compared to the stimulated 
control. Data correspond to n = 3. Scale bars = 50 μm. 
2.4.9. Migration Capacity of Human DPSCs Towards Healthy 
iMACs 
The chemoattractant properties of iMACs were evaluated by means of a transwell 
migration assay. Quantification of the migration area demonstrated the migration 
of DPSCs towards iMACs (Figure 2.9A). iMACs significantly attracted DPSCs after 
24  h of incubation; 30.84% ± 11.5% migration area percentage of DPSCs 
compared to 1.89% ± 1.8% for the negative control. 
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Figure 2.9. The migratory capacity of DPSCs towards iMACs after 24 h. The migration 
of DPSCs towards iMACs was evaluated using a transwell migration assay. (A) Quantification 
of the migration area demonstrated the migration of DPSCs towards iMACs (n = 5). (B) 
Representative pictures of the negative control, DPSC migration towards iMACs and positive 
control respectively. Scale bars = 500 μm. Data are represented as mean ± S.E.M. *. p ≤ 
0.05. 
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2.5. Discussion 
The suggested mechanisms via which MSCs mediate cartilage repair and aid in OA 
include replacement of damaged cartilage tissue and paracrine-mediated effects 
such as proliferation of endogenous cells and immunomodulation (6).  
In the first phase of the current study, the chondrogenic differentiation capacities 
of DPSCs were compared to BM-MSCs. Both BM-MSCs and DPSCs were shown to 
generate compact cartilage-like 3D spheres by differentiated cells surrounded by 
abundant ECM and GAGs. One of the most predominant PG, aggrecan, was not 
expressed in differentiated DPSCs, but cartilage spheres generated by BM-MSCs 
show abundant aggrecan secretion in the ECM. The absence of aggrecan in 
differentiated DPSC pellets in our study might be ascribed to several factors. One 
of these factors might be the differentiation time since an improved chondrocyte 
phenotype is reported upon prolonged culture times (226). After a differentiation 
period of 6 weeks, aggrecan expression was reported in human DPSCs by Mata 
and colleagues (144). However, Longoni et al. reported aggrecan expression after 
already 21 days of differentiation (227). Another possible explanation might be 
the used chondrogenic stimulus. The same research group stimulated cells by 
using TGF-β1, while the used chondrogenic stimulus in our study was TGF-β3 
(227). Though both isoforms have been described to be key in chondrogenesis, 
the distinct isoforms might be involved in different stages of chondrogenesis. In 
posterofrontal suture derived MSCs, for example, TGF-β3 significantly increased 
proliferation of mesenchymal cells, while TGF-β1 is involved in mesenchymal cell 
condensation thereby stimulating differentiation (228). Another factor might be 
the culture settings as many utilised scaffolds to improve the phenotype of DPSC-
derived chondrocytes in vitro, including hydrogels containing poly(ethylene glycol) 
dimethacrylate (PEGDMA), methacrylated gelatin (GelMA) and hyaluronic acid 
(HA) (145) and chitosan‐ based scaffolds (146), but did not always test for 
aggrecan expression. In addition, also hypoxic conditions and the addition of 
specific carbohydrates or growth factors might improve the expression of 
cartilage-specific components (154, 229, 230). Dai et al. reported that costal 
chondrocytes combined with exogenous FGF-9 are suitable to supply chondro-
inductive stimuli to DPSCs (147). Rizk and colleagues showed that TGF-β3-
transduced DPSCs express chondrogenic markers, including aggrecan (148). 
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Similar to our data, they showed that a positive staining for aggrecan was not 
evident in micromasses made by non-transduced DPSCs. Finally, the absence of 
aggrecan expression in our study might also have been influenced by inter-donor 
variability, as for example donor age might impact MSC differentiation (231, 232).  
Though DPSCs generated a GAG and collagen-rich matrix, when compared to BM-
MSCs, the lower GAG deposition and the absence of aggrecan suggest a 
differential chondrogenic potential. This might be associated with the fact that 
DPSCs are derived from the neural crest. In contrast to other bones of the body, 
which are derived from the mesoderm and ossify by endochondral ossification, 
bones from the craniofacial region originate from the neural crest and undergo 
intramembranous ossification during development (233). Moreover, neural crest 
cells are involved in the development of the temporomandibular joint (TMJ) and 
Meckel’s cartilage, which consist of fibrocartilage and hyaline cartilage respectively 
(227). Therefore, future studies should focus on the type of cartilage and the type 
of collagens that are being deposited by DPSCs. The latter has been addressed in 
a report of Longoni et al., in which they show that under various chondro-inductive 
conditions DPSCs formed more fibrocartilage-like tissues instead of hyaline 
cartilage (227). 
Chondrogenesis of MSCs has been shown to be enhanced by the supplementation 
of growth factors (154). The beneficial properties of L-PRF have mainly been 
attributed to the high concentration of platelets, leukocytes and the long-term 
release of growth factors by the L-PRF matrix (234). We investigated the effect of 
L-PRF ex and L-PRF CM on the chondrogenic differentiation of DPSCs and BM-
MSCs. Our results show that L-PRF ex and L-PRF CM were neither able to 
significantly increase the GAG secretion in both cell types nor induce aggrecan 
expression in DPSCs. Reports on chondro differentiation-promoting effects of 
platelets aggregates, such as PRP, on MSCs are contentious. Several previously 
confirmed chondro-inductive stimuli of platelet concentrates to MSCs (172, 235-
237), whereas others indicate that PRP treatment does not improve the in vitro 
chondrogenesis of MSCs (238). The difference between the previously identified 
differentiation-promoting effects of platelets aggregates such as PRP in 
musculoskeletal diseases (reviewed by Qian et al. (239)), and our data on L-PRF 
might be caused by different factors. First, various platelet concentrates have 
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different release kinetics (240). Second, compared to other platelet concentrates, 
L-PRF contains significantly higher concentrations of leukocytes (161). With 
reference to this, the leukocytes in L-PRF have positive effects (e.g. anti-microbial 
properties (161)), but might at the same time be involved in catabolic pathways 
(241). Moreover, the leukocyte fraction in L-PRF has been reported to be 
accountable for the overproduction of several growth factors, including VEGF and 
inflammatory cytokines (161, 242), which have been described to negatively 
impact chondrogenesis in vitro (221, 243-248). In contrast, many other growth 
factors present in L-PRF ex and L-PRF CM are reported to have beneficial 
influences on MSC chondrogenesis (164, 221, 249, 250). To date, our data 
strongly indicate that the supplementation of L-PRF ex and L-PRF CM does not 
alter MSC chondrogenesis in vitro. Moreover, while most studies focus on replacing 
the chondrogenic stimulus by a platelet concentrate, we studied the additive 
effects of L-PRF on chondrogenesis. In our experiments, the chondrogenic 
stimulus was not replaced by L-PRF exudate or L-PRF CM, but various 
concentrations of L-PRF exudate or L-PRF CM were added to the complete 
differentiation medium, which might also explain no enhancing effects since high 
levels of growth factors might be deleterious for tissue formation (251). Studying 
the inductive effect of L-PRF rather than the additive effect on chondrogenesis 
might therefore be an alternative future experimental approach. 
 
In a second phase, the secretome-mediated effects of human DPSCs and L-PRF 
on (TNF-α- and IL-1β-stimulated) iMACs were investigated. iMACs were isolated 
and phenotypically characterised based upon criteria identified by Gosset et al. 
(223). It is broadly documented that chondrocytes de-differentiate to fibroblast-
like cells in monolayer and can bias outcomes (223, 252). To overcome this, all 
data were generated using freshly isolated chondrocytes. TNF-α- and IL-1β-
stimulated chondrocytes transformed into cells with a reduced function, such as 
decreased cartilage-specific matrix mRNA levels, increased MMPs, inflammatory 
gene expressions and suppressed GAG production. These findings demonstrated 
the establishment of robust OA-mimicked chondrocytes in vitro. 
We demonstrated that L-PRF CM significantly enhanced unstimulated iMAC 
survival, proliferation and TNF-α- and IL-1β-stimulated iMAC viability in a 
concentration-dependent manner. These effects were not observed in iMACs 
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cultured in the presence of L-PRF ex. In contrast to our findings, Chien et al. 
demonstrated that the exudate of PRF could improve chondrocyte proliferation 
when cultured in fibrin-based scaffolds (169). This alteration in outcome between 
the two L-PRF derivatives might be explained in the difference in growth factor 
levels. Specifically, significantly higher levels of growth factors are found in L-PRF 
CM compared to L-PRF ex, which can be caused by the fact that L-PRF CM is 
generated after incubation for 96 h, resulting in a continuous release of growth 
factors by the leukocytes in the fibrin matrix of the L-PRF (159, 221). RT-qPCR 
data demonstrated at 24 h post-stimulation a significant decrease in aggrecan and 
collagen type II α 1 mRNA levels of healthy iMACs when cultured in the presence 
of L-PRF CM. L-PRF ex significantly decreased aggrecan mRNA expression. In 
addition, MMP-13 and TIMP-1 mRNA expressions were increased in unstimulated 
iMACs upon 25% L-PRF stimulation. The increased proliferative state of iMACs 
upon L-PRF CM supplementation seems to be accompanied by a downregulation 
of cartilage-specific ECM components and the upregulation of MMP-13 in healthy 
iMACs. When iMACs were cytokine-stimulated, L-PRF CM significantly increased 
MMP-13, TIMP-1 and IL-6 mRNA levels. ELISA demonstrated a significant increase 
of IL-6 and PGE2 secretion, two inflammatory mediators in OA by cytokine-
stimulated iMACs upon exposure to 25% L-PRF CM. IL-6 is widely known to 
mediate several pro-inflammatory responses contributing to the pathogenesis of 
several immune-related diseases, such as RA (253). Therefore, therapeutic 
targeting IL-6 has become important in the drug development applications of 
these diseases. Tocilizumab (TCZ), an IL-6 receptor-inhibiting monoclonal 
antibody, is widely used in the treatment of RA (254). However, the role of IL-6 
in OA remains unclear. High levels of IL-6 are found in the synovial fluid of OA 
patients. These high IL-6 levels are associated with increased MMP levels and 
radiographic OA changes (255, 256). Additionally, it was reported that inhibition 
of IL-6 with TCZ lowered pain behaviour in an experimental model of OA in rats 
(257). In contrast, IL-6 knockout mice revealed the progression of more advanced 
OA than wild-type animals and injection of IL-6 in the joint of IL-6-deficient mice 
reduced cartilage loss during arthritis (258, 259). Nevertheless, based on the 
above outcomes, our data might indicate an inability of L-PRF to counteract 
cytokine-induced phenotypical changes of iMACs in vitro. 
Dental Pulp Stem Cells and Leukocyte- and Platelet-Rich Fibrin for Osteoarthritis 
59 
Several growth factors, such as VEGF, EGF, IL-6 and MCP-1, are highly present in 
L-PRF CM and in minor levels in the exudate (221, 245) and might be accountable 
for the observed effects in the present study. For example, VEGF is reported to 
act as a survival factor in growth plate chondrocytes and has proliferative effects 
in immortalised chondrocytes (260). Moreover, increased MMP levels and 
secretion are reported because of VEGF (261, 262). Pufe and colleagues also 
showed pro-inflammatory factors such as IL-1β, nitric oxide, TNF-α and IL-6 to be 
induced by VEGF (262). Controversies concerning the impact of VEGF in cartilage 
repair and OA are stated. Hypoxia is needed to maintain proper chondrocyte 
phenotype. Via VEGF, this hypoxic state is reduced through increased vasculature, 
resulting in osteogenic-differentiating stimuli to form bone cells from chondrocytes 
(263). On the other hand, blocking VEGF was shown to inhibit chondroprogenitor 
cell proliferation and migration in vitro. Also, the complete inactivation of VEGF-A 
in areas of collagen type IIα1 expression resulted in embryonic lethality. These 
data indicate that a strictly controlled VEGF expression is indispensable for limb 
development, and thus chondrogenesis (263). Also EGF and IL-6 increased 
numbers of chondrocytes (264, 265). Furthermore, IL-6 is described to be able to 
increase MMP expression alone or in synergy with IL-1β and oncostatin M (266-
268). In addition, MCP-1 increased MMP-13 expression in chondrocytes (269). 
Furthermore, several other proteins that are abundantly present in L-PRF CM, 
such as RANTES, growth regulated oncogene (GRO) and IL-8 might be responsible 
for the observed effects in our study (221). RANTES is demonstrated to induce 
chondrocyte expression of iNOS, IL-6 and MMP-1 (270), while IL-8 and GROα are 
shown to induce articular chondrocyte hypertrophy and calcification through 
increased type X collagen, MMP-13 expression and alkaline phosphatase activity 
(271).  
In contrast to our findings, numerous other studies demonstrated that a large 
number of growth factors found to be secreted by platelet derivatives have 
predominantly beneficial and promising activities for (pre-)clinical applications for 
chondrogenesis and anti-inflammatory effects (165). To date, studies mainly 
focused on the role of platelets and platelet-derived growth factors, since these 
are the common features between all types of platelet concentrates, while future 
research should focus on identifying the role of the leukocytes and leukocyte-
derived growth factors and cytokines in L-PRF. To our knowledge, reports on the 
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secretome-mediated effects of L-PRF on chondrocytes in vitro are limited. 
Injectable-PRF, generated by a low speed centrifugation approach, was found to 
counteract IL-1β inflammatory effects in chondrocytes (170). In addition, Wong 
et al. treated chondrocytes with different concentrations of PRF CM and showed a 
proliferative effect on chondrocytes and induced chondrogenic differentiation of 
chondrocytes (171). Moreover, Barbon et al. revealed that preclinical studies 
strongly indicate a significant enhancement of cartilage regeneration after PRF 
treatment (164). There are several reasons for the discrepancy in outcomes 
between our study and studies proving beneficial effects of PRF in OA. First of all, 
the L-PRF used in our study was human-derived, while iMACs were from murine 
origin. This might have played a role in the inflamed and hypertrophic phenotype 
of iMACs cultured in the presence of inflammatory cytokines and L-PRF exudate 
or CM. Secondly, previous reports used a different form of PRF or employed an 
alternative differentiation protocol. One study used injectable PRF, which is 
produced by low-speed centrifugation (170). Wong et al. generated L-PRF CM by 
putting L-PRF clots, that were previously frozen, in medium for 24 h at 4 °C (171). 
Moreover, the exudate and CM fractions used in our study were centrifuged and 
filtered in order to be acellular, which has not been specified in other reports. 
Finally, inter-donor variability might be a crucial factor.  
In the present study, we show that the CM of DPSCs significantly enhances iMAC 
survival and proliferation in vitro. DPSC CM exerts the same, but smaller, effects 
on TNF-α and IL-1β-stimulated iMAC viability although not reaching statistical 
significance. DPSCs secrete various growth factors and cytokines, which might be 
accountable for the observed outcomes in the present study. Previous studies 
revealed high expression levels of TGFs and neurotrophic factors, including VEGF 
(219, 272, 273). Other factors present in the DPSC secretome involve but are not 
limited to IL-8, MCP-1, FGFs, MMPs, TIMP-1 (217, 219, 274). The presence of 
large quantities of VEGF in DPSCs could predominantly be responsible for the 
proliferative effects on iMACs (260). Narcisi et al. report that TGF-β1-stimulated 
chondrocytes evidenced increased mRNA levels for several hypertrophy-specific 
markers, including MMP-13, VEGF and TIMP-3 (275). In our study, RT-qPCR data 
show that DPSC CM induced significantly increased TIMP-1 expression in 
stimulated iMACs. TIMP-1 directly inhibits the activities of MMPs, thereby 
contributing to reducing the impact of MMPs (276, 277). Next to this, in cytokine-
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stimulated chondrocytes cultured on DPSC CM a not significant trend towards 
increased PGE2 production was observed. The role of PGE2 is controversial in OA; 
though PGE2 exerts catabolic functions in OA, one of the main effectors of MSC-
mediated immune-suppression is PGE2 (108).  
Cartilage-specific ECM production of iMACs in 3D culture after exposure to the 
secretome of L-PRF and DPSCs was also evaluated. The benefit of using these 
micromass cultures compared to monolayer cultures is that the 3D setting is more 
representative of the in vivo microenvironment. In consistence with our RT-qPCR 
results, cytokine stimulation of iMACs induced meaningfully less production of PGs 
and GAGs in micromass cultures, accompanied by increased nitrite secretion. 
Cartilage lacunae were more preserved by 3% L-PRF ex, 25% L-PRF CM and DPSC 
CM with a weak tendency of improved ECM content and chondrocyte status as 
compared to the stimulated control. Moreover, DPSC CM significantly decreased 
nitrite levels of iMACs cultured in 3D micromasses.  
It should be noted that the experiments in this study were conducted between 24-
72 h post-stimulation, a time window in which the outcome on matrix components 
like aggrecan or collagen type II production is not yet observed. Therefore, we 
also evaluated fast acting proteins such as nitrite and PGE2. Nonetheless, 
subsequent studies are necessary to investigate the impact on the structural level 
of cartilage by means of longer in vitro cultures, cartilage-explant studies and in 
vivo experiments. Moreover the use of the chosen GAG quantification method 
might be an important limiting factor. No quantitative analysis of GAG composition 
was performed via, for example, the dimethyl-methylene blue (DMMB) assay, 
which is one of the most available techniques to assess tissue composition and 
allows for normalization to DNA content. However, since the DMMB assay does 
not allow for the combination of visualizing both histological characteristics and 
GAG quantification in the same sample, quantification of histological stains was 
preferred. 
Concerning preclinical animal studies and since DPSCs show beneficial paracrine-
mediated impacts on OA, an IA injection of DPSCs might be of particular interest. 
With respect to this, we evaluated the migratory capacity of human DPSCs 
towards iMACs by means of a transwell migration assay and demonstrated that 
human DPSCs were able to successfully migrate towards iMACs. 
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Given the pathophysiology of OA, the role of immune cells, other cell types present 
in the synovial joint and synovial joint structures should ideally also be taken into 
account. Therefore, in order to supply a proper in vitro OA model, the interchange 
of immune cells, the synovial membrane and subchondral bone with the cartilage 
tissue and chondrocytes needs to be addressed. One-dimensional cell culture 
models cannot fully mimic the complexity of the OA pathophysiology. However, 
several advantages are associated with monolayer or one-dimensional cell 
cultures such as a large number of cells can be easily isolated, and cells in 
monolayer permit the homogenous spread of cytokines and nutrients. Still, co-
cultures or 3D cultures permit the study of cell-specific changes and cell–cell 
communications, while explant models inform on the induced alterations occurring 
in the ECM. The co-culture of the synovium with chondrocytes is one way to 
reproduce the complexity of the pro-inflammatory events in vitro. The use of bone 
in co-culture experiments is also crucial (278). Haltmayer et al. utilised a co-
culture system with all three principal tissues involved in OA, such as cartilage, 
subchondral bone and the synovium (279). 
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2.6. Conclusion 
The present study aimed to investigate the chondrogenic potential of both L-PRF 
and DPSCs in vitro in terms of being able to replace lost cartilage tissue, while 
having chondroprotective and immunomodulatory influences in OA chondrocytes. 
We show a discrepancy between BM-MSCs and DPSCs to form neo hyaline 
cartilage in vitro and that L-PRF did not improve or impede the chondrogenic 
differentiation of both DPSCs and BM-MSCs. However, DPSCs generated a GAG- 
and collagen-rich matrix, demonstrating that DPSCs are a promising cell source 
to make cartilage regeneration achievable. L-PRF CM exerted significant pro-
survival and proliferative effects on chondrocytes and increased several 
inflammation-related mediators involved in OA. Nevertheless, transformation into 
hypertrophic chondrocytes remains an important matter that needs to be further 
elucidated. Our data show promising therapeutic effects of DPSCs to repair 
cartilage lesions and in an in vitro model mimicking OA, as they can potentially 
replace the damaged cartilage tissue and act via secretome-mediated effects. On 
the one hand, DPSC CM can stimulate endogenous cells to proliferate and replace 
the lost tissue, while on the other hand, it could prevent the progression of 
cartilage loss by impairing chondrocyte apoptosis. Moreover, we indicate that 
factors secreted by DPSCs might cause multiple anti-inflammatory and anti-
catabolic influences in OA chondrocytes. In addition, the migratory capacity of 
human DPSCs towards chondrocytes might be essential in allowing IA injection of 
stem cells in future applications. Insights in the paracrine effects of DPSCs and 
understanding stem cell modulation will offer researchers a number of treatment 
options for musculoskeletal diseases and traumatic injury that have until now been 
limited by cell sourcing concerns. Finally, the influence of secretome-mediated 
actions of L-PRF and DPSCs on OA chondrocytes and other types of cells or joint 
structures involved in OA should additionally be investigated in longer-term co-
culture systems or 3D cell culture settings. Furthermore, since hypertrophic 
chondrocytes are important in pathological modifications in OA, a future study to 
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4.1. Abstract  
Due to the restricted intrinsic capacity of resident chondrocytes to regenerate the 
lost cartilage post-injury, stem cell-based therapies have been proposed as a 
novel therapeutic approach for cartilage repair. Moreover, stem cell-based 
therapies using mesenchymal stem cells (MSCs) or induced pluripotent stem cells 
(iPSCs) have been used successfully in preclinical and clinical settings. But before 
novel cell-based therapies for cartilage repair can be introduced into the clinic, 
rigorous testing in preclinical animal models is required. Preclinical models used 
in regenerative cartilage studies include murine, lapine, caprine, ovine, porcine, 
canine, and equine models, each associated with their specific advantages and 
limitations. The following chapter presents an overview of the advantages and 
disadvantages of utilizing small and large animals, while also describing suitable 
outcome measures for evaluating cartilage repair. 
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4.2. The Importance of a Translational Animal Model and 
Appropriate Outcome Measures  
While in vitro studies and models offer a substantial amount of information about 
the potential of stem cells for cartilage repair (308, 309), more in-depth 
knowledge about their behavior in vivo should be derived from immunocompetent 
animal models. In orthopaedic research, to move new technologies from bench to 
bedside, strict preclinical studies using translational animal models are required 
(310). Preclinical studies evaluating the healing of cartilage defects have been 
performed using both small and large animal models including murine, lapine, 
porcine, caprine, ovine, canine and equine models (63, 311). The following section 
will focus on the advantages and disadvantages of utilizing small and large animals 
for cartilage repair studies as well as some key factors in study design and the 
usage of validated outcome measures.  
4.3. Choice of Animal Model: Small Versus Large Animal 
Models 
Articular cartilage defects have been created in small animals, such as mice (91), 
rats (312-315) and rabbits (316-318). Smaller animal models are cost-effective 
and easy to house and rodents are available in a variety of genetically modified 
strains with minimal biological variability (17, 311). However, the small joint size, 
the thin cartilage (319, 320), altered biomechanics (321, 322), and increased 
spontaneous intrinsic healing (323) hamper the study of the regenerative capacity 
of stem cells and these mechanisms of healing cannot be fully extrapolated to 
human cartilage repair (17, 311). Rodents have mainly been used to assess 
chondrogenesis of cell-based therapies by subcutaneous (324), intramuscular 
(325), and intra-articular (IA) (326) implantations of cells (17). Of all small 
animals, the rabbit model is the most utilized model in cartilage regeneration 
studies because of the slightly larger knee joint size in comparison to rodents (63). 
Despite their limited translational capacity, small animals can be very useful as a 
proof-of-principle study and to assess therapy safety before moving on to 
preclinical studies using larger animals (17, 310).  
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Large animal models play a more substantial role in translational research because 
of a larger joint size and thicker cartilage, however, their preclinical use is often 
hindered by high costs and difficulties in animal handling. A variety of large animal 
models have been used to investigate cartilage repair strategies, including horses 
(327-329), dogs (330), sheep (331-335), goats (336, 337) and (mini)-pigs (338-
341), each with their own strengths and limitations.  
The knee anatomy (342-344), cartilage thickness (319, 345), biomechanical 
loading environment (311) and the subchondral bone properties (322) of the 
above-mentioned species differ variously from the human condition (311, 346). 
An advantage of using the porcine model is the cartilage thickness of 1.5 mm-2 
mm, compared to human cartilage thickness of 2.4 mm-2.6 mm (338, 345). Dogs, 
in contrast, have thinner cartilage (0.95 mm-1.3 mm) compared to human 
cartilage (311, 345). For the goat, cartilage thickness has been reported between 
0.8 mm and 2 mm, whereas cartilage thickness in sheep ranges from 0.4 mm to 
1.7 mm (311, 345). Of all animal models used in cartilage regeneration studies, 
the horse’s cartilage thickness (1.75 mm-2 mm) provides the closest 
approximation to the human situation (319, 322, 345, 347). 
In a comparative anatomical analysis, the goat stifle displayed strong anatomic 
similarities to the human knee except for a long trochlear groove with medial and 
lateral ridges and the intercondylar notch width (311, 342). According to Osterhoff 
et al., the ovine stifle is very similar to the human knee except for the femoral 
intercondylar notch width, the patellofemoral joint's biomechanics and the 
proximal tibia's cortical bone stock (344). More recently, Vandeweerd and 
colleagues described several anatomical features in the ovine stifle (343). 
Although the goat and ovine stifle are very similar to the human knee, these few 
anatomical differences remain and should be taken under consideration when 
selecting them as a suitable animal model (342-344), which, for instance, can 
have an impact on the volume of the synovial cavity. In addition to similar knee 
anatomy, the caprine model has been reported to have similar stifle biomechanics 
compared to human knees (311, 348). While the horse model offers defect sizes 
comparable to human defect dimensions, the increased weight and the fact that 
the horse spends much of its time in standing position place defects under 
significant loading and this continuous loading cannot be diminished (345). 
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Nevertheless, this constant loading environment in the horse stifle joint could be 
argued to be beneficial for translational cartilage repair studies since the human 
knee provides a less challenging load environment (349). Alternatively, ponies 
offer a good model; they closely mimic the human joint size and, in contrast to 
horses, have similar loads as humans (350). 
Moreover, since numerous repair strategies rely on the subchondral repair 
mechanisms, subchondral bone properties must be considered when selecting the 
appropriate repair model (322). According to Chevrier et al., the subchondral 
properties of the rabbit trochlea are similar to the human medial femoral condyle 
(MFC) (322). The goat offers advantages in subchondral bone consistency, 
thickness and trabecular structure, which are more similar to the human structure 
in comparison to either small animals, ovine or canine models (17, 311). A major 
disadvantage of the ovine and equine models is the dense and hard subchondral 
bone, while the caprine model has a softer subchondral bone (17, 345). In 
addition, subchondral bone cysts in sheep (331, 351) and goat (352) have been 
reported when the subchondral bone is involved in cartilage repair mechanisms 
(353).  
Ultimately, when selecting the best repair model, comparable anatomy and joint 
function are not the only important aspects, but other factors need to be taken 
into consideration when performing translational preclinical studies (Table 4.1). A 
factor requiring major consideration is the choice of defect location (311). 
Clinically, most defects are made on the femoral condyles or the trochlear groove 
(346). However, defect position influences cartilage repair response as 
demonstrated in caprine and ovine models leading to contradictory results (333, 
348). These differences in repair potential are due to differences in cartilage 
thickness, loading mechanics and subchondral bone properties within the knee 
and between species (322, 333, 348). In addition, defects may occur where higher 
loads are expected (354). Ideally, these areas should be used when defects are 
induced. Therefore, it is important to identify the prevalence of naturally occurring 
defects in animal models and to assess where the lesion should be created based 
on the biomechanics of the joint of the animal (311, 354). The ovine model is a 
well-documented model, where the most frequent naturally occurring cartilage 
defects in the ovine knee occur on the axial aspect of medial tibial condyle (MTC) 
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and on the MFC (354). Critical size chondral and osteochondral defects have been 
reported in rats, rabbits, dogs, (mini-)pigs, sheep, goats and horses (as shown in 
(310, 345, 355)). Skeletal maturity and animal age also affect repair mechanisms 
of cartilage defects, especially when the subchondral bone is fractured for 
induction of repair (322, 323, 353, 356, 357). Experimental models in animals 
that have reached skeletal and articular cartilage maturity are needed before the 
effect of any novel regenerative strategies on adult cartilage repair can be 
clinically evaluated. According to the International Cartilage Repair Society (ICRS) 
recommendations, selection of the age of an experimental animal should be based 
on cartilage maturity rather than on skeletal maturity (closure of the growth plate) 
(353). Cartilage maturity can be defined as the time point where a cartilage defect 
is not spontaneously repaired and at presence of a well-defined zonal architecture, 
an intact continuous layer of calcified cartilage, and minimal vascular penetration 
in the subchondral bone plate (353). This would confirm that the articular cartilage 
has the adequate cellular, biomechanical and biochemical properties. Therefore, 
in preclinical cartilage repair studies, animals at the age of cartilage maturity, 
defined based on the aforementioned conditions, should be used (Table 4.1) 
(353). 
While the choice of animal age, critical defect dimensions and location in preclinical 
studies is often justified, gender selection is frequently overlooked. Regenerative 
strategies to address cartilage lesions and osteoarthritis (OA) have not sufficiently 
considered possible gender differences (358). Therefore, potential gender effects 
must be taken more into consideration during analysis. Epidemiological studies 
demonstrated the presence of sex differences in OA prevalence and incidence with 
females being at a higher risk to develop more severe knee OA after reaching 
menopausal age (358). Several researchers examined the role of sex hormones 
in OA, including in ovine and murine models (354, 359-361). Ma and colleagues 
showed that sex hormones, both testosterone and oestrogen, have a crucial 
influence on the advancement of OA in mice. Testosterone aggravated the disease 
in male mice evidenced by the fact that orchiectomized mice showed a less severe 
OA than intact males. Healthy female mice showed less severe OA than 
ovariectomized females, demonstrating the protective role of female hormones 
(361). In a biomechanical study in sheep, ovariectomy in females induced a 
detrimental effect on the intrinsic properties of the articular cartilage in the knee 
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(359). In human subjects, differences in knee joint volume and articular surface 
areas between men and women have been described (362). Moreover, gender 
differences in cartilage composition and gait mechanics in young healthy, middle-
aged healthy, and OA cohorts are reported (363). These differences might 
influence functional outcome after repair (364). Thus, effective and well-designed 
regenerative preclinical studies are required and should lead to a better 
understanding of gender-specific differences in the mechanisms involved in 
cartilage re- and degeneration. Since OA and cartilage biology are reported to be 
sex-dependent, the inclusion of female animals is essential for preclinical cartilage 
repair studies. If both sexes are included, an equal number of males and females 
per study group with short ranges of ages should be used. Moreover, results 
should be reported for both genders and per study group (358). In addition, for 
large animals, it is more difficult to manage male animals, since sexual behaviour 
and mounting may increase loads on hind limbs.  
Obviously, the recommended study duration for evaluating cartilage repair in 
preclinical animal models is different for proof-of-concept or pilot studies (< 6 
months) versus late stage preclinical studies in large animal models (> 6 months) 
(310, 311, 353). However, for late stage preclinical studies, caution must be 
exercised when the study ends within a year or when no interval follow-up 
investigations are implemented since the repaired tissue can vary at earlier phases 
of healing and the sustainability of the repaired tissue is time-dependent (334, 
339, 353). Follow-up methods of noninvasive imaging are necessary (365, 366). 
Ovine models allow for imaging techniques such as magnetic resonance imaging 
(MRI) (353, 367), while the equine model is much more difficult, or impossible, 
due to size of animal versus size and costs of high-field MRI. Furthermore, the 
nature of the regenerative strategy, such as the use of autologous or allogeneic 
cell therapy, also needs to be considered. Both approaches have their own 
shortcomings. If autologous treatment includes site morbidity and logistic 
problems, allogeneic use forms an important risk factor for immune rejection or 
transmission of disease (368). Particularly, considering the differential influence 
of autologous, allogeneic or xenogeneic cells on the immune system and the 
impact on tissue repair (369), when aiming the development of tissue engineered 
constructs for cartilage repair, it is essential to consider the impact of the tested 
treatment on the immune response. 
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Other key issues in cartilage repair models are the choice of bilateral versus 
unilateral surgery and acute versus chronic defects (334, 353). Bilateral repair 
models are suitable to minimize inter-animal variability and to increase the 
number of treated limbs, but are only useful if the treatments are not reciprocally 
influencing the opposite limbs (370). Unilateral models, in contrast, ensure that 
the treatment is not influenced by the contralateral technique. In addition, these 
models allow easier joint immobilization and are exposed to less initial weight 
bearing on the operated limb. More importantly, unilateral models permit better 
evaluation of locomotion, range of motion and gait (353). 
Concerning the recommendations from regulatory bodies, the Food and Drug 
Administration (FDA), for example, has established that no perfect animal model 
exists for articular cartilage injury and both small and large animals should be 
included to assess safety, efficacy and durability of a treatment. However, they 
advise the use of large animals such as goats, sheep, and horses as suitable 
preclinical models (371). Moreover, various recommendation documents for 
preclinical cartilage repair studies are published by the FDA, European Medicines 
Agency (EMA), as well as the American Society for Testing and Materials (ASTM) 
International and ICRS and should preferably be applied. They provide a list of 
details for appropriate preclinical animal studies including commendations on 
study duration, lesion site, lesion location, use of cells and appropriate outcome 
measures (372). However, since these documents are not mandates but only offer 
advice, investigators can ultimately decide on the proper study design (372).  
The choice of animal model is also influenced by practical aspects such as ethical 
considerations, costs and availability of housing accommodations, materials and 
competent personnel (346). Nowadays, it is increasingly difficult to obtain ethical 
permission for the usage of dogs and horses, while working with reformed sheep 
or goats is less hindered by ethical rejection. Surgical limitations, such as the 
ability of the animal to tolerate anaesthesia and post-surgical recovery protocols 
or the possibility of second-look access, could influence the choice of a specific 
animal model (327, 328, 353, 373). The ovine model, for instance, is particularly 
easy to handle, cost-effective and easy to anaesthetize. 
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 Large difference in anatomy and biomechanics remain 
between animal models and humans 
Cartilage thickness  Large animals provide closer proximity to the human 
condition 
 Depends on topographic location in joint 
Subchondral bone 
properties 
 Effect on repair mechanisms 
 Depends on topographic location in joint 
Defect dimensions 
and location 
 Critical size chondral or osteochondral 
 Location of defect influences cartilage repair 
 Femoral condyles or trochlea 
 Defect should be made based on the biomechanics of 
the joint of the animal 
Age and gender  Age and gender may have effect on repair mechanism 
 Inclusion of skeletally mature animals with mature 
cartilage (human-near puberty): 
- Rat-13 weeks 
- Rabbit-8 months 
- Dog-24 months 
- Pig-18 months  
- Sheep-24 months 
- Goat-24 months 
- Horse-24 months 
 Gender effects must be taken into consideration 
 Use animals with short range of ages and with similar 
sex 
Study duration  Depends on type of study  
 Proof-of-principle (< 6 months) versus late stage 




 Unilateral versus bilateral repair models  
- Unilateral models: evaluation of locomotion, 
range of motion and gait, better immobilization, 
no influence of contralateral technique 
- Bilateral models: minimize inter-animal variability  
 Postoperative management should be tolerated 
 Ethical permission for small animals and ruminants is 
easier to obtain 
 Surgical feasibility must be taken into account 
 Financial costs to house and handle differ variously 
between animals 




 At baseline, in vivo and post mortem 
 Clinical response and kinematics  
 Biological fluid collection 
 Noninvasive compositional imaging MRI 
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 Ex vivo high resolution magnetic resonance imaging 
(MRI) or micro computed tomography (CT) 
 Tracking and monitoring 
 Macroscopic/arthroscopic scoring 
 Histological and histomorphometric scoring 
 Mechanical testing 
 Biomolecular and biochemical testing 
 
4.4. Follow-up and Outcome Measures 
Preclinical animal studies analysing the capacity of new technologies in cartilage 
regeneration frequently suffer from a lack of noninvasive follow-up and outcome 
measures and are therefore often forced to use endpoint outcome measures such 
as histology and destructive mechanical testing (Table 4.1). Additionally, there is 
an increasing need for standardized technologies with a diagnostic significance 
over the whole defect and adjacent tissues, while incorporating reflections of 
costs, care, ethics and mimicking the clinical investigations in human clinical trials 
(353, 365).  
For longitudinal in vivo studies, it is advised to assess the animal at baseline and 
at different time points. Depending on the animal, healthy joint status at the start 
of the study should be evaluated via diagnostic imaging modalities since variability 
in cartilage thickness, bone structure and the prevalence of naturally occurring 
cartilage defects and other lesions associated with OA can occur among species 
(354, 374-376). More specifically, spontaneously occurring cartilage lesions have 
been described in canine, equine and ageing ovine models (17, 353, 354). Canine 
and equine models should be screened for naturally occurring OA, since they can 
have lesions associated with OA or osteochondritis dissecans (17, 353). 
Noninvasive imaging of articular cartilage defects can be performed by MRI (377-
379) or computed tomography arthrography (CTA) (376, 380, 381). CTA has been 
shown to be more accurate than MRI to detect cartilage defects in humans (376, 
382). Hontoir et al. described CTA to be an accurate imaging method for detecting 
articular cartilage defects in the ovine stifle (376). Additionally, the same author 
compared the sensitivity and specificity of 3-Tesla (3-T) MRI and CTA to identify 
structural cartilage defects in the equine metacarpo/metatarsophalangeal joint. 
Hontoir and colleagues showed that CTA is superior to MRI due to its shorter 
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acquisition time, enhanced correlation to macroscopic assessment and its 
specificity and sensitivity in identifying articular cartilage defects, nonetheless MRI 
has the advantage to assess soft tissues and subchondral bone (380).  
For the visualization of cartilage, diagnostic imaging techniques such as 
ultrasound, computed tomography (CT) and MRI can be used (310, 365). More 
recently, novel quantitative MRI and CT techniques are being adopted as outcome 
measures after cartilage repair (365, 379, 381). Compositional imaging MRI is 
being progressively applied to assess the biochemical composition of cartilage for 
the longitudinal follow-up of cartilage repair studies (366). More specifically, T2 
mapping combined with delayed gadolinium-enhanced MRI of cartilage 
(dGEMRIC) seems to be a good compositional imaging modality to monitor 
cartilage repair and to discriminate between a collagen network with zonal 
organization and healthy cartilage (366, 383). Combining multiple imaging 
techniques may yield a better understanding of both the collagen and 
proteoglycan (PG) content of the repaired defect (384). T2 mapping provides 
information about the interaction of water molecules and the collagen network, 
while dGEMRIC evaluates glycosaminoglycan (GAG) concentration within cartilage 
(385). In human patients, Kurkijärvi et al. demonstrated that combining datasets 
from dGEMRIC and T2 relaxation time mapping provides additional information on 
cartilage repair (383). Recently, T2 mapping and dGEMRIC were used for 
assessing cartilage repair after allograft chondrocyte implantation in a rabbit 
model, where dGEMRIC data showed a high correlation with histological and 
biochemical data (385). In goat models, T2 mapping and dGEMRIC have also been 
used as outcome measures in a study evaluating cartilage repair after 
microfracture in an osteochondral defect of both the medial and lateral femoral 
condyles (386). One of the major disadvantages of using dGEMRIC is the necessity 
of administrating an intravenous contrast material (387). Alternatively, T1ρ has 
been used as a complementary imaging tool to T2 mapping which allows for the 
examination of PGs and the collagen organization and does not require the 
administration of a contrast agent (366, 387). Moreover, it offers information on 
early degenerative hallmarks and might offer prognostic values at baseline (387). 
Additionally, compared to T2 mapping, T1ρ might correlate better with 
macroscopic and histological characteristics of knee cartilage (388). However, one 
of the major issues of using T1ρ is reaching an adequate resolution with an 
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acceptable acquisition time and T1ρ is reported to be nonspecific in terms of 
cartilage components (366, 387). More recently, Van Tiel and colleagues showed 
that dGEMRIC is more robust in accurately measuring cartilage GAGs in vivo in 
patients compared to T1ρ mapping (389).  
Although substantial progress has been made in real-time in vivo cartilage 
imaging, spatiotemporal tracking of stem cells in vivo using MRI, bioluminescence 
imaging (BLI), fluorescence imaging (FLI) or nuclear imaging methods, should be 
the focus when developing novel imaging techniques (365). Superparamagnetic 
iron oxide (SPIO) particles are used for cartilage tissue engineering to monitor 
transplanted cells (390, 391). However, SPIO particles are associated with several 
drawbacks such as the inability to distinguish viable cells from dead cells and from 
cells engulfed by phagocytes (392). One of the possibilities to minimize particle 
transfer to other cells is the use of reporter genes. BLI compatible reporter genes 
such as red/green luciferases have already been used for cartilage tissue 
engineering to track transplanted cells (393). In addition, by labelling cells with 
an additional chondrogenic reporter gene, cell differentiation can be monitored by 
means of dual bioluminescence labelling (394). While this optical imaging method 
offers a sensitive technique to track stem cells, its use in larger animal models is 
limited because of a loss of signal intensity from deeper tissues due to scattering 
(395). 
At baseline and at longitudinal intervals, clinically relevant examinations of 
cartilage repair and functional improvement should be carried out. These should 
be performed by a veterinary surgeon familiar with observing clinical signs and 
locomotion by assessment of changes in joint palpation, quantitative monitoring 
of pain and changes in joint function or locomotion by gait analysis (310, 353, 
396-399). In rats, several scoring systems have been published to measure 
lameness, stride length and limb rotation, dynamic force application and hind limb 
motion (399). Moreover, for large animal models, kinematic marker analysis, 
ground reaction force measurements, and observational gait assessment have 
been progressively used in OA-related gait alterations in canine, ovine and equine 
models (399). Several scaling systems have been documented in the literature, 
such as the American Association of Equine Practitioners (AAEP) lameness scale 
in the horse ranging from zero to five (400). In ovine models, a numeric ranking 
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scale can be used to determine comfort, movement and flock behaviour (397). A 
more detailed lameness scoring system has been published by Kaler et al. ranging 
from ‘normal’ (0) to ‘unable to stand or move’ (6) (396). Overall, clinical 
assessment and gait monitoring are indispensable in order to increase the 
translational value of preclinical animal studies to human clinical trials and to the 
clinic.  
Biomarkers represent an additional tool to evaluate normal and pathological 
processes or to evaluate the interventional repair strategies (401, 402). These 
biomarkers may be identified and quantified via enzyme-linked immunosorbent 
assays (ELISA) or other protein assays in synovial fluid or other biological fluids 
such as in the blood and urine (401, 402). Synovial and other biological fluid 
collections should be performed at baseline and multiple time points (353), since 
synovial fluid biomarkers have the capacity to reflect the articular environment 
before treatment and could possibly inform on postoperative outcomes (401). In 
small animal models, however, it can be difficult to obtain sufficient amounts of 
biological fluid at multiple time points necessary for biomarker analysis (403). To 
solve this, the use of paper or alginate to obtain small amounts of synovial fluid 
has been described to be successful and effective (404). Because of the relatively 
larger joint size in large animal models, collection of synovial fluid and serum 
biomarkers can be more easily performed (347). Nevertheless, a major difficulty 
to perform repeated collections is the increased inflammation in the joint due to 
iatrogenic damage. Biomarkers of particular interest are markers for cartilage or 
synovium metabolism or markers involved in pathological pathways, such as 
inflammation (402). Recently, biological (synovial) fluid markers in OA were 
thoroughly reviewed by Nguyen and colleagues (402). Besides analyte 
quantifications to assess changes in inflammation and cartilage turnover, volume 
and physical characteristics of the synovial fluid, such as viscosity, could also be 
used as an outcome measure in preclinical studies (353).   
At the end of in vivo studies, cadaver tissue can undergo ex vivo high resolution 
MRI (405, 406) and CT (407) to evaluate structural improvements. Hereafter, 
macroscopic/arthroscopic scoring, histological and histomorphometric scoring 
methods, quantification of collagen and GAG expression by immunohistochemistry 
(IHC), collagen organization by polarized light microscopy and subchondral bone 
Chapter 4 
102 
and adjacent tissue integration are all outcome methods that should ideally be 
performed (407-411).  
Nowadays, many histological scoring systems are available, contributing to the 
confusion on the use of an appropriate scoring method for a specific research 
question and study settings (412). Moreover, it is unclear which scoring systems 
are validated and how study results can be compared between studies using 
different scoring methods (412). The variety of histological scoring systems for 
analysis of normal or OA, in vivo repaired or in vitro tissue-engineered cartilage 
was thoroughly reviewed by Rutgers et al. (412). Normal cartilage can be 
distinguished from OA cartilage via the Histological-Histochemical Grading System 
(HHGS) or HHGS-related systems and the Osteoarthritis Research Society 
International (OARSI) scoring method (412). Of the various scoring systems 
available for analysis of in vivo repaired cartilage, the ICRS II score seems most 
suitable in humans. In preclinical cartilage repair studies, the validated Pineda 
score or O’Driscoll score is advisable (412). Other histological scoring systems for 
preclinical cartilage repair are widely used. In addition to the Pineda Score, the 
Wakitani score is an elementary scoring system, reflecting not more than five 
parameters (413). The Pineda score assesses four histological parameters: cell 
morphology, matrix staining, lesion filling and osteochondral junction (413). The 
O’Driscoll score is a more complex histological scoring method which also assesses 
surface regularity, structural integrity, cellularity, chondrocyte clustering, 
adjacent bonding, and adjacent cartilage degeneration. In addition to the 
O’Driscoll score, also the Fortier and Sellers scores are more comprehensive 
scoring systems (413). Orth et al. showed that both elementary and 
comprehensive histological scoring systems are appropriate to quantify articular 
cartilage repair (413). However, complex scoring systems provide more 
descriptive data about the character of the repair tissue (413). The use of 
validated scores, such as the Pineda Score or the O’Driscoll score, may 
significantly increase comparability of information and should thus stimulate 
consistency between studies. Importantly, histological and biochemical 
evaluations are complementary tools to assess experimental articular cartilage 
repair in vivo (412). A key goal of regenerating mature cartilage tissue is to 
regenerate a tissue with biochemical/biomolecular and mechanical properties 
resembling those of native cartilage tissue. Small biopsies for biochemistry (water 
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content, GAGs/PG content and collagen content) and/or biomechanical testing 
should ideally be gathered before fixation of the repaired tissue for histology 
(410). In addition to typical end-point destructive measures to assess mechanical 
properties, indentation testing provides a non-destructive compressive technique 
for in situ mechanical evaluation (365, 414). Large animal models allow the 
harvest of a large amount of repaired tissue in order to have parallel histological, 
biochemical and biomechanical analyses of the repaired area post-mortem (353, 
415).  
Finally, the combined utilization of in vivo clinical tests and assessment of 
locomotion, in vivo noninvasive imaging methods, and post-mortem evaluation of 
tissue structure with validated scoring systems, biochemical composition, and 
mechanical properties will deliver a robust outcome analysis in order to improve 





Under ideal circumstances novel therapies are approved and released on the 
market after in vitro data were used to inform preclinical studies, which in turn 
lead to human clinical trials. Researchers should be aware that every animal model 
is associated with its advantages and disadvantages and the choice of model 
should match the research hypothesis and it is important to ensure proper 
translation to the clinic. Furthermore, the current lack of standardized protocols 
(i.e. cell delivery route, number of transplanted cells) as well as the wide variety 
of different outcome measures used to evaluate preclinical studies make it difficult 
to draw definite conclusions regarding the potential use of stem cell-based 
approaches in cartilage tissue engineering through direct comparison of studies. 
Furthermore, gender differences in most animal studies have not been adequately 




Musculoskeletal disorders (MSDs) include more than 150 diverse pathologies since 
they can affect but are not limited to muscles, bones, joints, cartilage, ligaments, 
and tendons. According to the World Health Organization (WHO), MSDs are the 
main cause for severe long-term pain and physical disability, and affect hundreds 
of millions of people around the world. Degeneration of the joint leads to injury to 
tissues from the joint, including articular cartilage and tendons. Cartilage injuries 
are very common, and form a risk factor for the development of osteoarthritis 
(OA), which is a degenerative and inflammatory condition of synovial joints with 
irreversible loss of supportive cartilage matrix. In addition to OA, over 30 million 
tendon-related surgeries take place per year worldwide with a significant socio-
economic burden. Moreover, tendon lesions represent 30% of all musculoskeletal 
consultations. Unfortunately, both OA and tendinopathy involve tissues that are 
characterized by a low intrinsic healing capacity and current treatment options are 
not able to provide full and stable recovery of the damaged tissue. Therefore, 
there is a growing need for the development of new treatment options for OA, 
cartilage defects and tendon injuries. Autologous chondrocyte implantation or the 
transplantation of tendon-derived stem cells have been proposed as efficient cell-
based therapies for treating chondral lesions or OA and tendon injuries 
respectively. However, the usage of adult autologous tissue-specific cells requires 
a two-step surgery and is associated with several other drawbacks. Therefore, 
innovative tissue engineering techniques exploiting compatible scaffolds and stem 
cells are currently needed. Stem cell-based therapies are seen as one of the most 
promising treatment strategies within regenerative research, since they have 
been widely used as therapeutic applications for many untreatable injuries and 
diseases.  
For stem cell-based strategies for OA or tendinopathies, mesenchymal stem cells 
(MSCs) are of particular interest. Most studies using a MSC-based cell therapy 
focus on bone marrow-derived MSCs (BM-MSCs). However, this type of MSC is 
associated with several downsides. First, the isolation of BM-MSCs is invasive and 
is associated with several complications. Secondly, BM-MSCs often result in 
hypertrophic differentiation. A promising alternative stem cell niche can be found 
in tooth-associated tissues, such as the dental pulp or the periodontal ligament 
tissue. Dental pulp stem cells (DPSCs) are isolated from the dental pulp and were 
first isolated by Gronthos et al. Since their first isolation, several others revealed 
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their MSC-like characteristics, including their immunophenotyping, plastic 
adherence and the ability to differentiate into classical mesodermal cell lineages; 
adipocytes, osteocytes and chondrocytes in vitro. In contrast to BM-MSCs, DPSCs 
showed a higher proliferative rate and have an easy isolation procedure by which 
they can be obtained. Additionally, the immunomodulatory properties of DPSCs 
emphasize their promise as cell-based therapies for immune-related diseases. 
Periodontal ligament stem cells (PDLSCs) are isolated from the periodontal 
ligament tissue and have been described to be a promising cell source for tendon-
regenerative applications because of their inherent ligamentous nature and their 
native expression pattern of tendon-associated markers.  
In addition to MSCs, platelet concentrates are emerging as promising treatment 
possibilities because of their high amount in growth factors and cytokines, which 
have been described to play crucial roles in wound healing and 
immunomodulation. However, since the well-studied platelet derivative; platelet 
rich plasma (PRP), requires the supplementation of anti-coagulants and 
biochemical handling before preparation, the use of leukocyte- and platelet-rich 
fibrin (L-PRF), a second generation platelet concentrate, is encouraged.  
In Chapter 2 of the current dissertation, we evaluated the therapeutic application 
of DPSCs and L-PRF in OA via immunomodulation and cartilage regeneration. 
Strong paracrine-mediated effects of DPSCs in an in vitro OA model were shown, 
as they undergo chondrogenesis in vitro, stimulate the survival of chondrocytes 
and have immunomodulatory effects. In contrast, L-PRF did not show promising 
secretome-mediated effects on OA chondrocytes and was unable to enhance 
chondrogenesis of DPSCs and BM-MSCs in vitro.  
In Chapter 3, we studied the ability of a three-dimensional (3D) growth condition 
under static tension and the supplementation of transforming growth factor-beta 
3 (TGF-β3) to generate in vitro tendon-like tissues of DPSCs and PDLSCs and 
compared them to BM-MSCs. In this chapter, we validated the feasibility of the 
usage of PDLSCs as a novel cell source for tendon repair. Cell alignment, cell 
density and gel contraction seemed to be improved in PDLSC-seeded constructs. 
All three stem cell types showed positive expression of tendon-related markers, 
tenascin C and tenomodulin. In contrast to BM-MSCs and DPSCs, PDLSC-derived 
constructs displayed the presence of collagen fibrils and less bone and cartilage 
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components. Taken together, our study validated the usage of PDLSCs as a novel 
cell source for tendon repair  
Before novel cell-based therapies for cartilage repair can be introduced into the 
clinic, rigorous testing in preclinical animal models is required. Preclinical models 
used in regenerative cartilage studies include murine, lapine, caprine, ovine, 
porcine, canine, and equine models, each associated with their specific 
advantages and limitations. Chapter 4 represents an overview of the advantages 
and disadvantages of utilizing small and large animals and different outcome 
measures to assess cartilage repair. Researchers should be aware that every 
animal model is associated with its drawbacks and the choice of model strongly 
depends on the research hypothesis to ensure the translation to the clinic. 
Furthermore, the current lack of standardized protocols as well as the wide variety 
of outcome measures used to evaluate preclinical studies make it difficult to draw 
definite conclusions regarding the potential use of stem cell-based approaches in 
cartilage tissue engineering through direct comparison of studies. 
Finally, for preclinical animal studies, the usage of autologous MSCs is the ideal 
approach to avoid rejection. In Chapter 5, we demonstrated that ovine DPSCs 
were effectively isolated from dental pulp tissue and showed morphological, 
phenotypical and functional properties similar to those observed in their human 
counterparts. We showed that ovine DPSCs may have potential use in 
osteochondral engineering. Moreover, because of promising paracrine-mediated 
effects by human DPSCs on OA-mimicked chondrocytes in vitro, preclinical OA 
studies in the ovine model using ovine DPSCs are encouraged. 
Nonetheless, the work in this thesis paves the way for preclinical studies that focus 
on DPSC-based stem cell therapies for OA. Future studies should aim to test their 
(autologous) efficacy in a large animal model of OA and focus on longitudinal 
follow-up with non-invasive imaging methods. Moreover, PDLSCs have been 
proposed to be a promising alternative source, when compared to DPSCs or BM-
MSCs, for cell-based regenerative treatment for tendon repair. However, future 
















Musculoskeletale aandoeningen omvatten meer dan 150 verschillende 
pathologieën aangezien ze spieren, botten, gewrichten, kraakbeen, ligamenten en 
pezen kunnen aantasten. Volgens de Wereldgezondheidsorganisatie zijn 
musculoskeletale aandoeningen de hoofdoorzaak van langdurige pijn en 
lichamelijke beperkingen en treffen honderden miljoenen mensen over de hele 
wereld. Degeneratie van het gewricht kan leiden tot letsels aan weefsels van het 
gewricht, waaronder gewrichtskraakbeen en pezen. Kraakbeenletsels komen erg 
vaak voor en vormen een groot risico voor de ontwikkeling van osteoartritis, een 
degeneratieve en inflammatoire aandoening van synoviale gewrichten met 
onomkeerbaar verlies van ondersteunende kraakbeenmatrix. Naast osteoartritis, 
vinden wereldwijd jaarlijks meer dan 30 miljoen pees-gerelateerde ingrepen 
plaats met een aanzienlijke sociaaleconomische last. Bovendien 
vertegenwoordigen peeslaesies 30% van alle musculoskeletale consultaties. 
Helaas hebben zowel osteoartritis als tendinopathieën betrekking tot weefsels die 
worden gekenmerkt door een laag intrinsiek regeneratie vermogen en de huidige 
behandelingsopties zijn niet in staat om volledig en stabiel herstel van het 
beschadigde weefsel te verzekeren. Daarom is er een sterke nood aan de 
ontwikkeling van nieuwe behandelingsopties voor osteoartritis, 
kraakbeendefecten en peesblessures. Autologe chondrocytenimplantatie of 
transplantatie van pees-stamcellen werden reeds voorgesteld als efficiënte cel-
gebaseerde therapieën voor de behandeling van respectievelijk chondrale laesies 
of osteoartritis en peesletsels. Het gebruik van autologe weefselspecifieke cellen 
vereist echter een tweestaps operatie en gaat gepaard met verschillende andere 
nadelen. Daarom zijn momenteel innovatieve weefseltechnieken nodig die gebruik 
maken van compatibele scaffolds en stamcellen. Stamcel-gebaseerde therapieën 
worden gezien als een van de meest veelbelovende behandelingsstrategieën 
binnen regeneratief onderzoek, aangezien ze voor veel onbehandelbare 
pathologieën op grote schaal onderzocht en gebruikt worden.  
Voor stamcel-gebaseerde behandelingsstrategieën voor osteoartritis of 
tendinopathieën bieden mesenchymale stamcellen (MSCs) bijzondere voordelen. 
De meeste MSC-gebaseerde studies richten zich vooral op beenmerg MSCs (BM-
MSCs). Dit type MSC gaat echter gepaard met verschillende nadelen. Ten eerste 
is de isolatie van BM-MSCs erg invasief en kan gepaard gaan met verschillende 
complicaties. Ten tweede resulteren BM-MSCs vaak in hypertrofische 
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differentiatie. Een veelbelovend alternatieve niche voor stamcellen zijn tand-
geassocieerde weefsels, zoals de tandpulp of het parodontale ligamentweefsel. 
Dentale pulpa stamcellen (DPSCs) worden geïsoleerd uit de tandpulp en werden 
voor het eerst geïsoleerd door Gronthos et al. Sinds hun eerste isolatie onthulden 
verschillende anderen hun MSC-achtige kenmerken, waaronder hun 
immunofenotypering, vermogen om te hechten aan plastiek en het vermogen om 
te differentiëren naar klassieke mesodermale cellijnen; adipocyten, osteocyten en 
chondrocyten in vitro. In tegenstelling tot BM-MSCs, vertoonden DPSCs een 
hogere proliferatief vermogen en hebben ze een gemakkelijke isolatieprocedure 
waarmee ze kunnen worden verkregen. Bovendien benadrukken de 
immunomodulerende eigenschappen van DPSCs hun veelbelovend gebruik voor 
immuun-gerelateerde ziekten. Parodontale ligament stamcellen (PDLSCs) worden 
geïsoleerd uit het parodontale ligamentweefsel en werden reeds beschreven als 
een veelbelovende celbron voor peesregeneratieve toepassingen vanwege hun 
inherente ligamenteuze aard en hun natuurlijke expressiepatroon van pees-
geassocieerde merkers. 
Naast MSCs worden plaatjesconcentraten meer en meer als veelbelovende 
behandelingsmogelijkheden voorgesteld vanwege hun hoge concentratie aan 
groeifactoren en cytokines, waarvan is beschreven dat ze cruciale rollen spelen 
bij wondgenezing en immunomodulatie. Echter, aangezien het bekende 
bloedplaatjesderivaat; bloedplaatjesrijk plasma (PRP), de toevoeging van anti-
coagulantia en biochemische behandeling vóór bereiding vereist, wordt het 
gebruik van leukocyten- en bloedplaatsjesrijk fibrine (L-PRF), een 
bloedplaatjesconcentraat van de tweede generatie, aangemoedigd. 
In Hoofdstuk 2 van het huidige doctoraatsproefschrift evalueerden we de 
therapeutische toepassing van DPSCs en L-PRF in osteoartritis via 
immunomodulatie en kraakbeenregeneratie. Sterke paracrien-gemedieerde 
effecten van DPSCs in een in vitro osteoartritis-model werden aangetoond, 
aangezien ze in vitro chondrogenese ondergaan, de overleving van chondrocyten 
stimuleren en immunomodulerende effecten hebben. Daarentegen vertoonde L-
PRF geen veelbelovende secretoom-gemedieerde effecten op osteoartritis-
chondrocyten en was L-PRF niet in staat de chondrogenese van DPSCs en BM-
MSCs in vitro te versterken. 
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In Hoofdstuk 3 bestudeerden we het vermogen van een driedimensionale 
celcultuur omgeving onder statische spanning en de toevoeging van transforming 
growth factor-beta 3 (TGF-β3) om in vitro peesachtige-constructen van DPSCs en 
PDLSCs te genereren en te vergelijken met BM-MSCs. In dit hoofdstuk hebben we 
het gebruik van PDLSCs als nieuwe celbron voor peesherstel gevalideerd. 
Celalignering, celdichtheid en gelcontractie waren sterker in PDLSC-afkomstige 
constructen. Alle drie stamceltypen vertoonden positieve expressie van pees-
gerelateerde merkers, tenascin C en tenomoduline. In tegenstelling tot BM-MSCs 
en DPSCs, vertoonden PDLSC-afkomstige constructen de aanwezigheid van 
collageenfibrillen en minder bot- en kraakbeencomponenten. Tot slot, heeft onze 
studie het gebruik van PDLSCs als een nieuwe celbron voor peesherstel 
gevalideerd. 
Vooraleer nieuwe cel-gebaseerde therapieën voor kraakbeenherstel in de kliniek 
kunnen worden geïntroduceerd, is rigoureus testen in preklinische diermodellen 
vereist. Preklinische modellen die worden gebruikt in regeneratieve 
kraakbeenstudies omvatten muizen, konijnen, geiten, schapen, varkens, honden 
en paarden, elk geassocieerd met hun specifieke voordelen en beperkingen. 
Hoofdstuk 4 geeft een overzicht van de voor- en nadelen van het gebruik van 
kleine en grote diermodellen en de verschillende evaluatiemethoden om 
kraakbeenherstel te bestuderen. Onderzoekers moeten zich ervan bewust zijn dat 
elk diermodel geassocieerd kan worden met nadelen en dat de keuze van het 
model sterk afhangt van de onderzoekshypothese om de translatie naar de kliniek 
te verzekeren. Bovendien maken het huidige gebrek aan gestandaardiseerde 
protocollen en de grote verscheidenheid aan evaluatiemethoden het moeilijk om 
definitieve conclusies te trekken over het mogelijke gebruik van stamcel-
gebaseerde behandelingsstrategieën voor kraakbeenweefsel door directe 
vergelijking van studies. 
Voor preklinische dierstudies zou het gebruik van autologe MSCs de ideale 
strategie zijn om afstoting te voorkomen. In Hoofdstuk 5 toonden we aan dat 
schaap DPSCs effectief geïsoleerd werden uit de dentale pulpa en morfologische, 
fenotypische en functionele eigenschappen vertoonden die gelijkaardig waren aan 
humane DPSCs. We toonden aan dat DPSCs van schapen mogelijk van belang 
zouden kunnen zijn voor osteochondrale engineering. Hierbij worden preklinische 
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osteoartritis-studies in het schapenmodel met schaap DPSCs aangemoedigd 
vanwege de veelbelovende paracrien-gemedieerde effecten van DPSCs in een 
osteoartritis model in vitro. 
Desalniettemin effent het werk in dit doctoraatsproefschrift de weg naar 
preklinische studies die zich richten op DPSC-gebaseerde stamceltherapieën voor 
osteoartritis. Vervolgstudies dienen zich te richten op het testen van hun 
(autologe) werkzaamheid in een groot diermodel van osteoartritis en zich richten 
op een longitudinale follow-up met niet-invasieve beeldvormingsmethoden. 
Bovendien werden PDLSCs als een veelbelovende alternatieve bron voorgesteld 
voor cel-gebaseerde regeneratieve behandelingen voor peesherstel. Toekomstige 
studies moeten er echter op gericht zijn hun doeltreffendheid in grotere 
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jullie stonden altijd voor me klaar! Merci om mij altijd met de voetjes op de grond 
te houden wanneer ik mij iets te hard opjoeg. Merci voor alle leuke babbeltjes en 
etentjes (Petra, merci voor de “SATC” DVD box! Heb ik zeker kunnen gebruiken 
als pauze tijdens het schrijven van mijn thesis)!  
De collega’s van gebouw D, Liliane, Dennis, Davy, Marc en Jeanine, jullie 
verdienen ook zeker een plekje in mijn dankwoord. Bedankt voor de vele 
babbeltjes, gezellige lunchpauzes, paaskebabs en kerstfeestjes! Marc, bedankt 
voor het snijden van de TEM coupes! Jeanine, bedankt voor de meters aan 
paraffinecoupes die je voor mij gesneden hebt! Je hebt een belangrijke bijdrage 
geleverd aan de foto’s in het boekje!  
Leen, Igna, Katrien, Petra, Christel en Kim, ook jullie verdienen zeker een 
plaatsje in dit dankwoord. Dank je wel voor al jullie hulp en technische 
ondersteuning. Leen en Katrien, merci het beantwoorden van al mijn vragen over 
qPCR en immunokleuringen! 
En natuurlijk ook een grote dankjewel aan alle andere BIOMED-collega’s die de 
afgelopen jaren me hebben bijgestaan en altijd klaar stonden voor een babbeltje 
op de gang of aan het koffietoestel! 
Je voudrais aussi remercier tous les collègues de Namur pour leur patience et leur 
aide. Mon français n'était pas toujours parfait, mais vous vous êtes toujours 
assurés que nous ayons toujours une conversation agréable et facile. Fanny, 
Vincent, Hélène, Yves, Lucie et Françoise, merci pour tout! Je tiens tout 
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particulièrement à remercier Hélène et Vincent! Je n'oublierai jamais les jours 
glacials des sessions d’ultrason! Fanny, merci pour l’aide avec l’administration de 
mon doctorat! 
De voorbije jaren zijn er ook heel wat studenten gepasseerd en hebben ze 
allemaal bijgedragen aan mijn doctoraat. Joel, mijn (minion) seniorstudent, al 
was het in het begin even wennen om met mijn “loco”-gehalte te kunnen omgaan, 
hebben we samen heel wat plezier gehad in en uit het labo. Je hebt mooie 
resultaten afgeleverd en ben dan ook niet verbaasd dat jij nu ook aan een 
doctoraat begonnen bent. Wouter en Jonathan, ook jullie bijdrage was enorm 
belangrijk voor mijn onderzoek! Merci voor jullie hulp! 
Kristel en Regine, dank jullie wel voor het zuiver houden van onze bureau en 
celkweek-labo. Kristel, bedankt voor alle gezellige babbeltjes! Als ik ooit twee 
jaarlang zal rondreizen, ga jij zeker met mij mee!  
Ten slotte wil ik ook graag alle vrienden en familie (vooral de nichten) bedanken 
voor hun onvoorwaardelijke steun tijdens mijn doctoraat! Stephanie, dankjewel 
voor alles! Als ik wat afleiding kon gebruiken, stond je altijd voor mijn deur! Merci 
voor de gezellige etentjes of koffietjes in Bioville wanneer ik het nodig had. 
Mama, papa, Dario, Syria, Manu, Aldo, Ale, Loredana en Riccardo, ondanks 
jullie je meer dan eens hebben afgevraagd wat mijn grafieken en fotootjes 
betekenden, hebben jullie mij altijd gesteund en bleven jullie geïnteresseerd in 
mijn onderzoek! Bedankt om mij eeuwig te steunen in alles wat ik doe! PS: Dario, 
bedankt voor Zorro :), mijn knuffelbeer, die elke avond na het werk klaar stond 
voor een knuffel en voor de nodige afleiding zorgde wanneer het wat minder goed 
ging. 
Tot slot, Federico … als er iemand is die ontzettend veel geduld heeft gehad de 
voorbije jaren, dan ben jij dat! Je hebt altijd in mij geloofd, altijd wist je mij rustig 
te houden en bent altijd super fier op mij geweest. Ik ben ook ontzettend trots als 
ik jou hoor babbelen over mijn onderzoek. Sorry voor al de keren dat ik ‘s avonds 
laat uit bed sprong omdat ik de celkweek was vergeten te reserveren of als ik nog 
snel een analyse wou nakijken (om 1u ‘s nachts :)). Sorry voor de avonden van 
de voorbije maand dat ik aan mijn thesis moest werken en jij dan maar de 
tafel/keuken moest afruimen (hoewel mijn lange werkavonden u heel wat game-
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uren hebben opgeleverd :)). Het is zeker niet gemakkelijk geweest om een huis 
te bouwen met mij terwijl ik aan mijn doctoraat bezig was en jij zelf ook een 
drukke job hebt. Gelukkig, heb je er altijd voor gezorgd dat de liters aan wijn en 
prosecco klaar stonden! Fede, danku… voor alles!  
Melissa, oktober 2020 
 
